Drug, bio-affecting and body treating compositions inventions 10/08

20080260635 - Cytotoxicity mediation of cells evidencing surface expression of mcsp: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.A.

20080260634 - Diagnostic use of endothelin etb receptor agonists and eta receptor antagonists in tumor imaging: Methods of imaging tumors are disclosed. The methods utilize an endothelin ETB receptor agonist or an endothelin ETA receptor antagonist, in combination with an imaging agent, to detect a tumor in mammals, including humans.... Agent: Marshall, Gerstein & Borun LLP

20080260636 - Stabilization of radionuclide-containing compositions: Described are methods for stabilizing radionuclide-containing compositions against degradation caused by free radicals generated from the radionuclide. Iodide ions stabilize the radionuclide-containing compositions by acting as scavengers to generated free radicals, thus, preventing or lessening degradation therefrom. Among the preferred radionuclide-containing compositions to be stabilized are complexes of a complexing... Agent: Millen, White, Zelano & Branigan, P.C.

20080260637 - Methods of detecting prostate cancer: A method of detecting presence or absence of prostate cancer in a subject, both in vivo and ex vivo is disclosed. The method comprises analyzing mitochondria or a mitochondrial component in at least one prostate cell of the subject, whereby mitochondria an alteration in quantity and or characteristic is indicative... Agent: Martin D. Moynihan Prtsi

20080260639 - Preparation and method utilizing radiolabeled chlorotoxin: The inventors propose to label a chlorotoxin with I-123 or I-124 for a diagnostic agent, and with I-124 or I-131 for a therapeutic agent to reduce tumors and then to use a process they previously invented to stabilize the radiopharmaceutical. The inventors propose to reconstitute the preferred agents and administer... Agent: Brooke Schumm Iii Daneker, Mcintire, Schumm, Prince, Goldstein Et Al

20080260638 - Receptor(sstr2)-selective somatostatin antagonists: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4... Agent: Fitch Even Tabin And Flannery

20080260642 - Bacteriophage-based contrast agents, the use thereof and a method for the production thereof: Bacteriophage-based contrast agents and a method for the production thereof are disclosed. The bacteriophages, in at least one embodiment, contain a first fusion protein comprising a phage-surface protein and a ligand specific for an identifiable target structure and a second fusion protein comprising a phage-surface protein and a peptide binding... Agent: Harness, Dickey & Pierce, P.L.C

20080260641 - Human monoclonal antibodies against cd20: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080260640 - Use of precursors of tachykinins and/or their fragments in medical diagnostic: The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other biological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of... Agent: Heslin Rothenberg Farley & Mesiti PC

20080260644 - Chloride transport upregulation for the treatment of traumatic brain injury: Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.... Agent: Dann, Dorfman, Herrell & Skillman

20080260645 - Method and use of cold-pressed botanic seed oils for lowering blood pressure and ldl cholesterol: m

20080260643 - Use of pde7 inhibitors for the treatment of movement disorders: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080260646 - Imaging reporters of transgene expression: Disclosed are compositions and methods for imaging in animals.... Agent: Morgan, Lewis & Bockius LLP (sf)

20080260648 - Pharmaceutical preparation containing magnetic vesicular particles, manufacturing method thereof and diagnostic therapeutic system: s

20080260649 - Method of dynamic nuclear polarisation dnp: The invention relates to a method of dynamic nuclear polarisation (DNP) using a combination of a trityl radical and a paramagnetic metal ion as the polarising agent leading to enhanced levels of polarisation in the sample to be polarised and to compositions and polarising agents for use in the method.... Agent: Ge Healthcare, Inc.

20080260650 - Methods of detection and therapy of inflamed tissues using immune modulation: The present invention relates to methods for the detection and therapy of inflamed tissue, whereby immune modulators are used to increase the uptake of diagnostic or therapeutic compositions by inflammatory cells.... Agent: Ewards Angell Palmer & Dodge LLP

20080260651 - Contrast agents: e

20080260647 - Method for fluorescence tomographic imaging: There is provided a method for determining the concentration of a fluorophore in a medium using moments of order k of the fluorescence signal. The method allows higher fidelity 3-dimensional reconstructions of the fluorophore in the medium. The method can be applied in imaging of fluorophores in biological tissues.... Agent: Bereskin And Parr

20080260652 - Composition for dyeing dental plaque for evaluating dental caries activity: An objective of the present invention is to provide a composition for dyeing dental plaque for evaluation of dental caries activity that is capable of simultaneously dyeing dental plaque and evaluating dental caries activity, and which can evaluate thick dental plaque more accurately than the conventional technique. The composition for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260655 - Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses: The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further... Agent: Wilmerhale/boston

20080260654 - Sustained release composition of protein drug: Disclosed is a sustained release composition of a protein drug. The composition comprises a carrier substrate and a protein drug incorporated in the carrier substrate. The carrier substrate is consisting essentially of a hyaluronic acid or its salts, an amino acid, and a polyalkyl oxide.... Agent: Cantor Colburn, LLP

20080260653 - Transdermal delivery systems and transdermal chelation preparations: The invention provides topical chelating preparations and formulations. The invention provides methods of transepithelial delivery of a topical chelating preparation to a human or other animal by topical application to the skin of a human or animal of a topical chelating preparation. In one aspect, a preparation or formulation of... Agent: Morrison & Foerster LLP

20080260656 - Ungual/periungual compositions comprising morpholine compounds and water-soluble film-forming agents: Pharmaceutical compositions suited for ungual and periungual application and useful for the treatment of dermatological conditions/afflictions, in particular onychomycosis, contain an anti-mycotic agent of the family of the morpholines and a water-soluble film-forming agent.... Agent: Buchanan, Ingersoll & Rooney PC

20080260657 - Process for milling poorly soluble drugs in presence of liquid propellants: Drug substance for use in a pharmaceutical formulation may be prepared by a process which process comprises co-milling a suspension of the drug substance and a pharmaceutically acceptable polymer in a liquid propellant.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080260659 - Compositions: The invention is directed to personal care products and compositions that comprise at least one preservative compound selected from the group consisting of benzoic acid, p-hydroxy-benzoic acid, methyl-paraben, ethyl-paraben, propyl-paraben, isopropyl-paraben, butyl-paraben, isobutyl-paraben, benzyl-paraben, or a salt thereof, in a total concentration of 0.1% to 0.5% (w/w); and at least... Agent: Norris, Mclaughlin & Marcus

20080260658 - Hair setting compositions based on t-butyl acrylate and hydroxyalkyl methacrylate: The present invention relates to copolymers, which comprises, in copolymerized form, between 25 and 80% by weight of tert-butyl (meth)acrylate, 2 to 60% by weight of hydroxyalkyl (meth)acrylate, 10 to 40% by weight of an anionic or anionogenic, free-radically polymerizable, olefinically unsaturated compound which is or comprises methacrylic acid, and,... Agent: Connolly Bove Lodge & Hutz, LLP

20080260660 - Teeth whitening agents: The invention relates to light-activated teeth whitening compositions, and to the use thereof for lightening teeth. The inventive whitening agent contains riboflavin and or the derivatives thereof, which enable the oxidant in the whitening agent to decompose more rapidly, by means of radiation energy, thus effectively accelerating the whitening action.... Agent: Edwards Angell Palmer & Dodge LLP

20080260661 - Aminobutadiene-based uv screens: The invention relates to the use of an UV-absorbing compound for the preparation of a cosmetic composition for protection against UV radiation said compound being represented by the general formula (I) wherein less than 10% of the total absorption between 250 and 600 nm of said UV-absorbing compound according to... Agent: Foley And Lardner LLP Suite 500

20080260663 - Esterification reaction products and cosmetic products: e

20080260662 - Sunscreen compositions comprising carotenoids: The invention concerns methods of treating or preventing the effects of irradiation in a human or non-human animal using carotenoid compounds, preferably diadinoxanthin, diatoxanthin and/or fucoxanthin as well as photoprotective compositions and their use to prepare photoprotective or photoprotected products.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080260664 - Particles functionalized with organic compounds: The present invention relates to particles comprising an inorganic network and organic compounds covalently bonded to the network via a spacer group, where the organic compounds are present in the interior of the particles and optionally also on the surface of the particles. The present invention furthermore relates to processes... Agent: Millen, White, Zelano & Branigan, P.C.

20080260665 - Nail varnish comprising at least one polycondensate and at least one polyoxyalkylene copolymer: copolymers comprising at least one polyethylene glycol block and at least one polypropylene glycol block, the said copolymer exhibiting a molecular weight of greater than or equal to 1000 g/mol and their mixtures.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260666 - Cosmetic compositions comprising at least one non-ionic surfactant and at least one vinylamide/vinylamine copolymer and methods of use thereof: p

20080260667 - Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin:

20080260668 - Method for preparing a compound for drawing a non-permanent tattoo and a method of using said compound: The present invention refers to a method for preparing of a compound for drawing a non-permanent tattoo from the “jenipapo” fruit (Genipa americana). A certain amount of juice from the “jenipapo” fruit (Genipa americana) is provided, into which a thickener is added for forming a substantially creamy compound, which receives... Agent: Ronald R Santucci Frommer Lawrence Haug LLP

20080260669 - Aromachemicals: wherein R1 and R2 represent, independently, linear or branched C1-4 alkyl, n=0 to 4 and m=0 to 3. Mixtures of these compounds, methods for their preparation, their use as perfume materials for application to a variety of substrates and their use in flavouring and in articles of manufacture is also... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080260670 - Organic compounds: e

20080260672 - Aqueous preservative solution with high amino acid content: Aqueous preservative solutions with a high amino acid content which is excellent in preservation, particularly a preservative effect on fungi, and safety, and is excellent in storage stability so as not to cause a problem such as depositing, coloring or smelling even when it is stored for a long time,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260671 - Depilatory compositions: A depilatory composition comprising a depilatory compound having a thiol group and a quinone and/or phenol compound.... Agent: Merchant & Gould PC

20080260674 - Cosmetic use of amphoteric polysaccharide compounds containing cationic polymer chain (s): The invention relates to the cosmetic use, especially for the cosmetic treatment of keratin materials, of amphoteric polysaccharide compounds containing cationic polymer chain(s), which may be obtained by grafting and polymerization of ethylenic monomers of formula (I), Q− onto an anionic polysaccharide of formula (II): in the presence of a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260675 - Depolymerized scleroglucan for regulating and improving the moisture content of the skin: The use of depolymerized scleroglucan alone, or in combination with one or more active ingredients as a moisturizer, and as anti-inflammatory active ingredient for protecting and for restoring a healthy skin barrier in the field of cosmetic or dermatological skincare is disclosed.... Agent: Scully Scott Murphy & Presser, PC

20080260673 - Conditioning composition: The present invention is related to composition for conditioning keratin fibres especially human hair with reduced bulk density. The inventors of the present invention have found out that a conditioning composition comprising at least one shear thickening polymer and at least one conditioning compound and having reduced bulk density solves... Agent: Norris, Mclaughlin & Marcus, P.A.

20080260676 - Hydroxycucurbituril derivatives, their preparation methods and uses: Provided are hydroxycucurbituril derivatives, their preparation methods and uses. The hydroxycucurbituril derivative is easy to further functionalize with enhanced solubility in common solvents, thereby providing wider applications.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080260677 - Transdermal topical composition and its uses: An emollient component is provided in a composition, suitable for topical application to skin, comprising a fugitive solvent base comprising at least one alcohol. One advantage of the invention is that the irritancy potential of the composition due to the alcoholic fugitive solvent base is reduced.... Agent: Catalyst Law Group, Apc

20080260679 - Methods and compositions for treatment of ion imbalances: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment... Agent: Senniger Powers LLP

20080260678 - Molecular band-aid: A molecular sealant comprising a therapeutically effective amount of a poloxamer capable of sealing a cell or tissue from leaks. A method of treating tissue leakages by applying the above sealant to the tissue or cell in need of treatment. A composition for treating cellular leakages comprising a poloxamer capable... Agent: Warner Norcross & Judd LLP

20080260680 - Method of attenuating reactions to skin irritants: The present invention is directed to a method of inhibiting CDld activation by administering a composition containing a moiety that blocks CDld activation. Compositions of the invention are useful for the attenuation of CDld-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for... Agent: Wilson Sonsini Goodrich & Rosati

20080260681 - Compositions and methods for treating and preventing cardiomyopathy and heart disease: The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188-P1 88) and methods of using the same for treating and preventing heart disease (e.g., in subjects with muscular dystrophy) and for treating cells and... Agent: Tyler J. Sisk Casimir Jones

20080260682 - Polyethylene glycol colonic purgative composition: This invention relates to novel colonic purgative compositions of polyethylene glycol having an average molecular weight of at least 1,000 or at least 4,000. Further, this invention relates to methods of using the colonic purgative compositions. The formulations and methods of this invention are particularly useful to cleanse the bowel... Agent: Edwards Angell Palmer & Dodge LLP

20080260683 - Rodenticide: The invention relates to the systemic insecticide fipronil in conjunction with a rodenticide used for manufacture of a bait composition to provide a lethal effect on fleas and/or ticks and a host rodent, following ingestion of the bait composition by the host rodent. Preferred rodenticides are brodifacoum, difethialone, flocoumafen, bromadiolone... Agent: Fish & Richardson PC

20080260684 - Method for the purification of g-csf: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying... Agent: Knobbe Martens Olson & Bear LLP

20080260685 - Prodrugs of cc-1065 analogs: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a... Agent: Sughrue Mion, PLLC

20080260686 - Methods of using il-31 to treat airway hyper-responsiveness and asthma: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness... Agent: Zymogenetics, Inc. Intellectual Property Department

20080260688 - Novel inhibitors of glutaminyl cyclase: e

20080260689 - Peptides for active anti-cytokine immunization: Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080260687 - Specific binding agents for kshv vil-6 that neutralize a biological activity: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds... Agent: Klarquist Sparkman, LLP

20080260690 - Interferon in influenza: The use of an interferon (IFN) for the manufacture of a medicament for treatment and/or prevention of influenza, preferably avian influenza, is described in the present invention.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080260691 - Prodrugs of ribavirin with improved hepatic delivery: The present invention relates ribavirin delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to ribavarin and methods for administering conjugated ribavirin compositions.... Agent: Darby & Darby P.C.

20080260692 - Spirulin composition rich in active principles, method for obtaining same and use thereof: The invention relates to a spirulina combination composed of at least two distinct strain types from the genus Arthrospira, particularly Arthrospira LONAR and Arthrospira PARACAS whose phycocyanin content is between 13 and 30%, a method for obtaining such a combination, a composition containing this combination, and its use as a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080260693 - Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (lcmv): The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.... Agent: Viksnins Harris & Padys Pllp

20080260707 - Isolated homozygous stem cells, differentiated cells derived therefrom and materials and methods for making and using same: The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed... Agent: Patton Boggs LLP

20080260705 - Preventing arrhythmias associated with cell transplantation: Skeletal myoblasts are an attractive cell type for transplantation since they are autologous and resistant to ischemia. However, clinical trials of myoblasts transplantation in heart failure have been plagued by ventricular tachy-arrhythmias and sudden cardiac death. The pathogenesis of these arrhythmias is poorly understood, but may be related to the... Agent: Banner & Witcoff, Ltd.

20080260706 - Transient transfection with rna: A method of mRNA production for use in transfection is provided, that involves in vitro transcription of PCR generated templates with specially designed primers, followed by polyA addition, to produce a construct containing 3′ and 5′ untranslated sequence (“UTR”), a 5′ cap and/or Internal Ribosome Entry Site (IRES), the gene... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080260694 - Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof: The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.... Agent: Cooper & Dunham, LLP

20080260695 - Composition for prevention and/or treatment of cancer: The invention relates to a composition for use in the prevention and treatment of cancer. The composition includes fermented soy extract, oligomeric proanthocyanidin, epigallocatiechin gallate, spirulina, curcumin and Antrodia camphorata. The composition of the invention effectively prevents the growth of cancer cells, especially colorectal cancer, ovarian cancer, breast cancer, cervical... Agent: Birch Stewart Kolasch & Birch

20080260696 - Method for decreasing inflammation and oxidative stress in mammals: The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to decrease a level of an oxidized glutathione and/or increase the... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080260708 - Methods and related systems and formulations to normalize and improve human body chemistry and healing ability: Methods, systems and formulations for normalizing and improving human body chemistry and the body's natural ability to heal itself. In one embodiment a system including effective amounts of a digestive enzyme, soluble and insoluble fiber, laxative, probiotics, vitamin C, potassium, protease enzymes, lipase, lysine, taurine, proline, choline, inositol, inositol hexaphosphate,... Agent: Greenberg Traurig LLP (la)

20080260709 - Cholesterol-lowering agents, secondary bile acid production inhibitors and foods and drinks: Secondary bile acid production inhibitors and cholesterol-lowering agents containing a yeast as the active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260697 - Bacterial management in animal holding systems: The present invention is directed to method for reducing a population of a target pathogen in an animal or within a feedlot. The method involves administering one or more than one controlled release bacteriophage strain or phage component, or both, to the animal, so that the one, or more than... Agent: Brinks, Hofer, Gilson & Lione

20080260698 - Chimeric sindbis-western equine encephalitis virus and uses thereof: The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment, an Eastern equine encephalitis virus cDNA fragment, a Western equine encephalitis virus cDNA fragment or a combination thereof. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays.... Agent: Benjamin Aaron Adler Adler & Associates

20080260699 - Adminstration of intact mammalian cells to the brain by the intranasal route: The present invention provides an intranasal method for delivery of intact mammalian cells to the brain for treatment of neurological deficits. This approach applies an intranasal instillation to directly administer cells to the brain, and is useful as therapy for patients with neurological deficit or those who may benefit from... Agent: Richard Aron Osman

20080260701 - Anti-angiogenic cellular agent for cancer therapy: The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When... Agent: Beyer Weaver LLP

20080260704 - Combination treatment of cardiovascular disease: Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.... Agent: Baumgartner Patent Law

20080260700 - Generation of pancreatic endocrine cells from primary duct cell cultures and methods of use for treatment of diabetes: The invention is directed to spontaneously immortalized pancreatic duct cells and methods for generating pancreatic endocrine cells from spontaneously immortalized pancreatic duct cells that express the transcription factors Pdx1 and FoxO1. The invention also provides for methods for treating beta cell failure, the method comprising administering to a subject an... Agent: Wilmerhale/columbia University

20080260703 - Treatment of insulin resistance and diabetes: Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular... Agent: Baumgartner Patent Law

20080260702 - Treatment of retinopathies using gfra3 agonists: The present invention relates to the use of GFRα3 agonists for the treatment of disorders of the retina. A preferred GFRα3 agonist is Neublastin. Neublastin may be administered to the eye using protein formulations, in vivo or ex vivo gene therapy, or implantation of encapsulated cells delivering Neublastin locally to... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080260710 - Method for suppressing surgical site infection and column to be used for the method: An object of the present invention is to provide a method for suppressing surgical site infections (SSI) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method.... Agent: Greenblum & Bernstein, P.L.C

20080260711 - Detoxifizyme with activity of transforming aflatoxin and the gene encodes thereof: The present invention relates to a detoxifizyme with the activity of transforming aflatoxin and the gene encodes thereof. Inventors firstly isolate and purify a novel protein, named aflatoxin-detoxifizyme (ADTZ), which has the activity of transforming aflatoxin. The primes specify to the ADTZ gene are obtained through purification and sequencing. The... Agent: Myers Dawes Andras & Sherman, LLP

20080260712 - Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability: A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize... Agent: Robert Berliner Berliner & Associates

20080260714 - Fibrin compositions containing strontium compounds: A composition for use in bone healing and bone regeneration in the form of a viscoelastic hydrogel gel or liquid formulation comprising fibrinogen, thrombin and an inorganic component comprising a strontium (Sr) containing compound and/or possibly another metal such as a calcium containing compound. The strontium containing compound can be... Agent: Howrey LLP - Dc

20080260713 - Neukinase, a downstream protein of neuregulin: The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies,... Agent: Jones Day

20080260715 - Precursor n-acetylgalactosamine-4 sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme: The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including... Agent: Marshall, Gerstein & Borun LLP

20080260716 - Method and composition for high level disinfection employing quaternary ammonium compounds: Methods and compositions for high level disinfection (as herein defined) of a surface. Methods include treating the surface with a composition including a quaternary ammonium compound in a concentration which exceeds 1% w/w and the temperature of treatment is in the range of from 30° C. to 80° C. A... Agent: Edwards Angell Palmer & Dodge LLP

20080260724 - Drug induced exposure of the fungal pro-inflammatory molecule beta-glucan: Methods and reagents for screening for anti-microbial agents are provided. Diagnostic tools for assessing treatment of fungal infections are provided. Antimicrobial substances including substances useful for the treatment of fungal infections are provided. In some embodiments, the substances have antigen unmasking activity. In some embodiments the substances have fungicidal activity... Agent: Proskauer Rose LLP

20080260719 - Edg: modulators of lymphocyte activation and migration: The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates... Agent: Klarquist Sparkman, LLP

20080260722 - Method for high efficiency survival/proliferation of human embyonic stem cells and human embryo survival in culture: The present invention provides a role for neurotrophins in hES cell survival and important new insights into the molecular mechanisms controlling the growth of these cells. Although previous studies identified growth factors that affect self-renewal of hES cells, the novelty of the present invention is the identification of factors that... Agent: Edwards Angell Palmer & Dodge LLP

20080260723 - Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one... Agent: Law Office Of John K. Pike, PLLC

20080260717 - Methods for reducing seizure-induced neuronal damage: This invention provides a method for treating a subject either during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure comprising administering to the subject, either during or soon after the seizure, a therapeutically effective amount of an... Agent: Cooper & Dunham, LLP

20080260721 - Nucleic acids encoding a mammalian raptor polypeptide and uses therefor: The present invention relates to isolated raptor nucleic acid molecules of mammalian origin (e.g., human) and complements, portions and variants thereof. Another aspect of the invention are isolated raptor polypeptides of mammalian origin and portions thereof, and antibodies or antigen binding fragments thereof that specifically bind a raptor polypeptide. The... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080260726 - Organic compounds: A method of identifying a substance suitable for use in inhibiting mucus hypersecretion that modulates the activity of a human cathepsin C gene or its gene product. The method involves combining a candidate substance with the human cathepsin C gene or its gene product and measuring the effect of the... Agent: Novartis Institutes For Biomedical Research, Inc.

20080260718 - Phospholipase c gamma modulation and uses thereof for management of pain and nociception: The present invention provides methods of preventing and treating pain, by modulating, e.g. inhibiting, the activity, function and/or expression of a PLCγ in a subject. The invention further relates to methods of identifying agents capable of modulating the activity and/or expression of a PLCγ, or capable of modulating binding of... Agent: Ladas & Parry LLP

20080260720 - Systems and methods for inhibiting metastasis: The present invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for inhibiting cancer metastasis by inhibiting G12 and G13 activity.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080260725 - Tag and target delivery system: A system for targeting dividing cells and delivering therapeutic agents to the targeted cells using a Tag nanoparticle. Each Tag nanoparticle comprises a nucleotide encoding a Tag, which is expressed only in dividing cells. The system optionally utilizes a microparticle to deliver Tag nanoparticles to cells. Therapeutic nanoparticles comprising therapeutic... Agent: Ratnerprestia

20080260732 - Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis: The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.... Agent: Howrey LLP-ca

20080260734 - Compositions and methods for characterizing, regulating, diagnosing, and treating cancer: The present invention relates to compositions and methods for characterizing, regulating, diagnosing, and treating cancer. For example, the present invention provides compositions and methods for inhibiting tumorigenesis of certain classes of cancer cells, including breast cancer cells and preventing metastasis. The present invention also provides systems and methods for identifying... Agent: Casimir Jones, S.c.

20080260733 - Humanized collagen antibodies and related methods: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic... Agent: Wilson Sonsini Goodrich & Rosati

20080260729 - Method of treating cancer comprising a vegf-b antgonist: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their... Agent: Scully Scott Murphy & Presser, PC

20080260727 - Modulation of nkg2d: The present invention relates to methods and compositions for treating or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells and/or NK cells, by modulating NKG2D.... Agent: Medlen & Carroll, LLP

20080260731 - Optimized antibodies that target cd19: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20080260735 - Transfer request (37 cfr 1.821(e)) humanised antibodies to the epidermal growth factor receptor: The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080260730 - Treatment of crohn's disease or psoriasis using anti-interferon gamma antibodies: The present invention provides a method of treating autoimmune diseases. In particular, it provides a method for the treatment of Crohn's disease or psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of an antibody against interferon γ.... Agent: Townsend And Townsend And Crew LLP

20080260728 - Treatment of severe multiple sclerosis: Methods of treating multiple sclerosis are disclosed.... Agent: Fish & Richardson

20080260737 - Combination of blys and/or april inhibition and immunnosuppressants for treatment of autoimmune disease: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment... Agent: Zymogenetics, Inc. Intellectual Property Department

20080260736 - Methods and compositions to regulate iron metabolism: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in... Agent: Clark & Elbing LLP

20080260738 - Single chain fc, methods of making and methods of treatment: The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080260740 - Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080260739 - Use of anti-mortalin 2 antibody and functional nucleic acid for cancer therapies: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific... Agent: Sughrue Mion, PLLC

20080260746 - Erythropoietin polypeptides and uses thereof: The present invention relates to EPO polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080260744 - G protein coupled receptors and uses thereof: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists)... Agent: Seed Intellectual Property Law Group PLLC

20080260743 - Means and methods for detecting methylated dna: The present application relates to a nucleic acid molecule having a nucleotide sequence encoding a bifunctional polypeptide comprising the DNA-binding domain of a protein belonging to the family of Methyl-CpG binding proteins (MBDs) and the Fc portion of an antibody. In addition, vectors and host cells which comprise said nucleic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260747 - Methods and materials relating to cd84-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of... Agent: Nuvelo, Inc

20080260741 - Preventive and/or therapeutic agent for cancer: As the results of intensive studies aiming at providing a gene targeting a cancer cell or a cancer tissue, novel nucleotide sequences showing increased expression in a cancer cell or a cancer tissue compared with normal tissues are identified. As the results of the subsequent studies, genes showing increased expression... Agent: Edwards Angell Palmer & Dodge LLP

20080260742 - Preventives/remedies for cancer: The present invention provides preventives/remedies for cancer and so on. Specifically, an antibody against a protein comprising the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 17, SEQ ID NO: 25, SEQ ID NO: 38... Agent: Edwards Angell Palmer & Dodge LLP

20080260745 - Targeted identification of immunogenic peptides: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific... Agent: James Remenick Novak Druce & Quigg, LLP

20080260748 - Methods for damaging cells using effector function of anti-dsc2 antibody: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides... Agent: Townsend And Townsend And Crew, LLP

20080260749 - Novel tetrahydropyridothiophenes: e

20080260750 - Polynucleotides encoding acetylcholine-gated chloride channel subunits of caenorhabditis elegans: The invention relates to novel polynucleotides which encode novel polypeptides that are acetylcholine-gated chloride channel subunits and immunogenic or acetylcholine-binding fragments thereof. The novel polypeptides may be used for identifying compounds that modulate the acetylcholine-gated chloride channels, e.g. for use as pesticides and antiparasitic agents. Methods for identifying compounds that... Agent: Smart & Biggar P.o. Box 2999, Station D

20080260751 - Methods and compositions for the modulation of immune responses and autoimmune diseases: The present invention relates to a regulation of inflammation and immune responses. The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an activator of RP105. The condition is typically associated with TLR-4 activation and cytokine production. Conditions addressed by the invention... Agent: Frost Brown Todd, LLC

20080260752 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary... Agent: Lowrie, Lando & Anastasi, LLP

20080260754 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Rigel Pharmaceuticals Inc.

20080260753 - Mouse models of crohn's disease and a method to develop specific therapeutics: Provided are compositions, transgenic animals and methods for screening and analyzing agents useful for treating inflammatory bowel diseases. Also provided are methods to treat inflammatory bowel disease, Crohn's disease and Blau syndrome.... Agent: Buchanan, Ingersoll & Rooney LLP

20080260756 - Peptide inhibitors of iaspp: The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide.... Agent: Marshall, Gerstein & Borun LLP

20080260755 - Proteolytically cleavable fusion proteins with high molar specific activity: The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260757 - Bispecific fusion antibodies with enhanced serum half-life: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080260758 - Universal gm-csf expressing bystander human k562 cell line: The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition.... Agent: Barnes & Thornburg LLP

20080260761 - Compositions, splice variants and methods relating to cancer specific genes and proteins: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of... Agent: Licata & Tyrrell P.C.

20080260762 - Hla binding motifs and peptides and their uses: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080260759 - Novel mite allergen: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or... Agent: Greenblum & Bernstein, P.L.C

20080260760 - Prostate-specific antigen-derived mhc class h-restricted peptides and their use in vaccines to treat or prevent prostate cancer: The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more... Agent: Evans & Molinelli, PLLC

20080260766 - Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti-hiv-1 prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention: e

20080260763 - High throughput proteomics: Methods to obtain expression systems and proteins in a high-throughput protocol by utilizing mixtures of cells cultured from those transformed with a desired nucleotide sequence permit rapid production of protein for use in arrays to assess activity. In one embodiment, the proteins (or peptides) in the array are assessed for... Agent: Fish & Associates, PC Robert D. Fish

20080260765 - Hpv dna vaccines and methods of use thereof: Human papillomavirus (HPV) infection is the etiological factor for cervical cancer. Provided are HPV vaccines that generate a humoral immune response to prevent new infection, as well as cell-mediated immunotherapy to eliminate established infection or HPV-related disease. HPV vaccines include nucleic acid sequences encoding HPV16 early proteins E6 and E7.... Agent: Foley Hoag, LLP (w/jhv)

20080260764 - Replikin peptides and uses thereof: The present invention provides isolated influenza peptides and nucleic acid sequences and methods of identifying said influenza peptides and nucleic acid sequences having a pattern of substitution of amino acids or nucleic acids in highly conserved Replikin and Replikin Scaffold sequences that is predictive of rapid replication and virulence. Methods... Agent: Kenyon & Kenyon LLP

20080260767 - Novel protein which can be used, in particular, for the in vitro isolation and prevention of legionella pneumophila infections: The invention relates to novel polynucleotides, including SEQ ID NO: 1 or parts or variants of the sequence, novel polypeptides encoded by the polynucleotides, expression vectors including the polynucleotides and host cells including the expression vectors. The polynucleotides and polypeptides can be used in the field of in vitro diagnosis... Agent: Young & Thompson

20080260768 - Streptococcus pneumoniae proteins and nucleic acid molecules: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.... Agent: Hunton & Williams LLP Intellectual Property Department

20080260769 - Polypeptides for oligomeric assembly of antigens: A system for expressing antigenic polypeptides in oligomeric form fuses the antigenic polypeptide to an oligomerisation polypeptide such that the oligomerisation polypeptide can interact with other oligomerisation polypeptides and bring multiple copies of the antigenic polypeptide into close proximity in the form of an oligomer. Expressing the polypeptides in oligomeric... Agent: Novartis Vaccines And Diagnostics Inc.

20080260770 - Use of tellurium compounds as adjuvants: Methods for enhancing the immune response of a subject to an immunoeffector, and methods of enhancing interleukin-12 production, which are effected by administering an amount of the immunoeffector and an effective adjuvanting amount of a tellurium-containing compound are provided. The enhanced immune response may be a cell-mediated or a humoral... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20080260772 - Extract from agaricus blazei murill capable of suppressing breast cancer: A food material capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer. An extract of Agaricus Blazei Murill comprising an ingredient capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer is provided. This ingredient can be a chromatographic main elution... Agent: Perkins Coie LLP

20080260771 - Prostate disorder(s) phyto-nutraceutical synergistic composition: A Phyto-nutraceutical composition for the prevention and treatment of prostate disorders is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effect.... Agent: Jose Olalde Rangel

20080260774 - Alpha-galactosyl ceramide analogs and their use as immunotherapies: wherein, n is 0 to 25; X is selected from O and S; R1 is selected from H, CH3, and phenyl, where phenyl is optionally substituted with H, OH, OCH3, F, CF3, phenyl, phenyl-F, C1-C6 alkyl, or C2-C6 branched alkyl; R2 is selected from OH and H; R3 is selected... Agent: Greenberg Traurig LLP (la)

20080260773 - Saccharide conjugate vaccines: The invention provides compositions comprising a combination of two or more monovalent conjugates, each of said two or more monovalent conjugates comprising a carrier protein comprising T cell epitopes from two or more pathogens conjugated to saccharide antigen. The invention also provides a multivalent conjugate comprising two or more antigenically... Agent: Novartis Vaccines And Diagnostics Inc.

20080260775 - New live virus vaccines: The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an... Agent: Myers Bigel Sibley & Sajovec

20080260776 - Preparation of salmonella broad-spectrum vaccines: The present invention relates to a pharmaceutical composition providing protective unity against a broad spectrum of Salmonella enterica serovars.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080260777 - Composition and method for controlling intestinal pathogenic organisms: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field strains of E. coli, Pseudomona aeruginosa, Aerobacter aerogenes, Salmonella enteritidis, Salmonella typhimurium, Salmonella agona, and Salmonella Kentucky. The antigen, composition can be used alone or in combination... Agent: Amin Hallihan, LLC

20080260778 - Method of vaccination against testicular bvdv infection: The methods of the invention relate to methods for preventing testicular infection by bovine viral diarrhea virus by immunizing susceptible male animals against infection.... Agent: Pharmacia & Upjohn

20080260779 - Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080260780 - Materials and methods relating to improved vaccination strategies: The invention provides novel vaccination strategies based on a prime-boost vaccination regiment. The inventors have determined improved ways of boosting an immune response in a patient previously primed or exposed to a plurality of epitopes. The improved method requires the epitopes in the boosting phase to be administered individually, i.e.... Agent: Foley And Lardner LLP Suite 500

20080260781 - Proteosome influenza vaccine: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080260782 - Mycobacterium avium subspecies paratuberculosis vaccines and methods of using the same: The invention relates to vaccine compositions composed of at least one Mycobacterium avium subspecies paratuberculosis (MAP) antigen, or attenuated or killed MAP for use in methods of immunizing a human against a MAP infection, preventing or treating a MAP infection, and preventing a human disease associated with a MAP infection.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20080260783 - Composition and method for controlling intestinal pathogenic organisms: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes naturally-occurring wild Salmonella enterica subspecies in O-serogroups B, C2 and D. Subspecies in O-serogroup B can include Salmonella typhimurium and/or Salmonella agona. Subspecies in O-serogroup C2 can include Salmonella... Agent: Amin Hallihan, LLC

20080260784 - Compositions and methods for modulating an immune response: The present invention provides a composition for suppressing an inflammatory immune response comprising the excretory/secretory (ES) component of Fasciola hepatica or a fraction thereof. The composition has particular utility in the treatment or prophylaxis of T cell mediated inflammatory immune responses, and in particular autoimmune disease. The invention further extends... Agent: Marshall, Gerstein & Borun LLP

20080260785 - Paroxetine compositions: The invention relates to pharmaceutical compositions having polymers that release paroxetine in a controlled manner for a prolonged or sustained period of time. An embodiment of the invention provides enhanced bioavailability controlled release pharmaceutical compositions comprising paroxetine or its pharmaceutically acceptable salts, which enables a reduction in its orally administered... Agent: Dr. Reddy's Laboratories, Inc.

20080260786 - Process for making encapsulated particles: Method for preparing an active-containing starch matrix and the free flowing, dry powder that results from such a process. The active ingredients can be released (deposited) onto a surface by normal triggering mechanisms, which include the action of a liquid or by friction or rubbing. The fixative systems described herein... Agent: National Starch And Chemical Company

20080260787 - Use of collagen in combination with oxygen- and ozone-releasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions: A medicament and a medication for the treatment of skin lesions are disclosed, which comprise collagen and an oxygen-carrying and releasing fluorinated hydrocarbon and, optionally and preferably additionally, ozone. Particularly, the invention relates to a kit for the topical administration of such a medicament on the damaged skin, as well... Agent: Pearne & Gordon LLP

20080260788 - Skin cleaning composition: The present invention describes a skin cleaning and disinfecting composition comprising an active component, wherein the active component comprises at least one alcohol, at least one halogen. The present invention also describes corresponding anti-bacterial, anti-viral and anti-fungal compositions, as well as a method of manufacturing same.... Agent: Greenberg Traurig LLP (la)

20080260789 - Insecticidal polypeptides and methods of use thereof: A family of insecticidal polypeptides expressed in the venom gland of spiders of the genera Atrax and Hadronyche have been described. Also included are polynucleotides and expression vectors encoding the polypeptides and insect viruses and cells expressing the polypeptides. Transgenic plants and insects expressing the insecticidal polypeptides are also described.... Agent: Johathan P. O''brien Miller, Canfield, Paddock And Stone, P.L.C

20080260791 - Injectable capsaicin: The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting... Agent: Davidson, Davidson & Kappel, LLC

20080260792 - Method to use therapeutic microencapsulation of embedding parathyroid live cells with theracyte: A method to use a therapeutic microencapsulation of embedding parathyroid live cells with a TheraCyte comprises the steps of: (1) containing the parathyroid live cells in −179° C. liquid nitrogen and then unfrozen for preparing the therapeutic microencapsulation; (2) embedding at least 4×105 parathyroid live cells in the TheraCyte to... Agent: Nikolai & Mersereau, P.A.

20080260790 - Plasmid enhancement agent for high intensity focused ultrasound treatment and use thereof: The present invention discloses a plasmid enhancement agent for high intensity focused ultrasound (HIFU) treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a nanometer-sized biocompatible solid. The present invention also discloses another plasmid enhancement agent for HIFU treatment, wherein, the... Agent: The Webb Law Firm, P.C.

20080260793 - Porous gelatin material, gelatin structures, methods for preparation of the same and uses thereof: The present invention relates to a porous gelatin material in the form of spherical particles with a continuous pore structure and cast, three-dimensional, porous gelatin structures. The invention also comprises methods for preparation of the porous gelatin materials and structures. The method for preparing the porous gelatin material in the... Agent: Morgan Lewis & Bockius LLP

20080260798 - Aligned scaffolds for improved myocardial regeneration: The present invention relates to a biocompatible, three-dimensional scaffold useful to grow cells and to regenerate or repair tissue in predetermined orientations. The scaffold is particularly useful for regeneration and repair of cardiac tissue. The scaffold contains layers of alternating A-strips and S-strips, wherein the A-strips within each layer are... Agent: Fulbright & Jaworski L.L.P.

20080260799 - Bioactive implant and method of use: The invention relates to a method for producing bioactive implant surfaces consisting of metallic or ceramic materials, to be used for implants such as artificial joints or very small implants such as so-called stents. The invention also relates to implants produced according to this method and methods of using the... Agent: Foley & Lardner LLP

20080260794 - Collagen products and methods for producing collagen products: Medical implants and methods for forming a medical implant blends a dispersion of human collagen fibers and/or threads and optionally a volume between about 2 to about 15% of an alcohol and forms medical implants by removing a liquid component of the collagen dispersion. Medical implants formed include collagen films,... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080260797 - Methods of treating disease with nitric oxide (no)-releasing polymers and soluble no-releasing nitrosamines: The invention provides NO-releasing polymers and low molecular weight NO-releasing compounds which may be used to for the treatment of medical conditions associated with NO-deficiency. The NO-releasing polymers or the low molecular weight NO-releasing compounds may also be incorporated into medical devices. The invention further provides methods of controlled release... Agent: Michael Best & Friedrich LLP

20080260796 - Reduction of infection associated with medical device: Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.... Agent: Campbell Nelson Whipps, LLC

20080260795 - Strong reversible hydrogels: The present invention relates to improved hydrogel materials using water gellants that are comprised of polymer backbones P to which hydrogen bonding 4H-units are covalently attached via a hydrophobic linker L. Optionally, the hydrogel contains additional ingredients or additives. These new reversible hydrogels can easily be fine-tuned in their mechanical... Agent: Foley And Lardner LLP Suite 500

20080260800 - Extracellular matrix cancer vaccine adjuvant: Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described... Agent: Bell, Boyd, & Lloyd LLP

20080260802 - Biocompatible hydrogels made with small molecule precursors: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable, or not, are provided,... Agent: Dardi & Associates, PLLC

20080260801 - Composite material, especially for medical use, and method for producing the material: o

20080260803 - Sustained release intraocular inplants containing tyrosine kinase inhibitors and related methods: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix... Agent: Stephen Donovan

20080260804 - Medical devices having antimicrobial coatings thereon: The present invention provides a medical device, preferably a contact lens, which comprises an antimicrobial coating including at least one layer of polyquat of formula (I) or (II). The antimicrobial coating on the medical device of the invention has a high antimicrobial efficacy against microorganisms including Gram-positive and Gram-negative bacterial,... Agent: Ciba Vision Corporation Patent Department

20080260805 - Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to... Agent: Hoffmann & Baron, LLP

20080260808 - Device for smoothing wrinkles on human skin: Device for smoothing wrinkles on human skin and for enabling skin sections between successive wrinkles to achieve prolonged contact with cosmetic and/or pharmaceutical substances carried by said device.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260806 - Personal hygiene compositions and methods: A personal hygiene composition, which may be coated on a towelette, comprises an astringent, a humectant, and a botanical extract. In some embodiments, the botanical extract can be selected from the group consisting of Hydrastis Canadensis, Tabebuia Impetiginosa, Hymenaea Courbaril, Ptychopetalum Olacoides, Juniperus Brasiliensis, Hamamelis Virginiana, and mixtures thereof. The... Agent: Harness, Dickey & Pierce, P.L.C

20080260809 - Polyethylene oxide-based films and drug delivery systems made therefrom: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component,... Agent: Hoffmann & Baron, LLP

20080260807 - Water-soluble films comprising nicotine: A water-soluble film comprising nicotine, wherein said nicotine may be any pharmacologically effective form of nicotine present at one or more locations of the film defined by the application of a nicotine-containing fluid to at least one surface of a preformed water-soluble film.... Agent: Mcdermott Will & Emery LLP

20080260810 - Hemostat: The present invention is directed towards a hemostat comprising an absorbable foam, an absorbable woven or knitted fabric, thrombin and/or fibrinogen.... Agent: Philip S. Johnson Johnson & Johnson

20080260811 - Transdermal delivery systems: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form... Agent: Thomas P. Mccracken Durect Corporation

20080260812 - Therapeutic medicine containing monoclonal antibody against folate receptor beta (fr-beta): An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260813 - Pharmaceutical composition of topiramate: The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical... Agent: Philip S. Johnson Johnson & Johnson

20080260814 - Injection moulding process for neutral and acid-group-containing (meth)acrylate copolymers: Processes for producing moldings by injection moulding, include melting a mixture made from a (meth)acrylate copolymer and a release agent, devolatilizing the mixture, injecting the molten and devolatilized mixture into a mold cavity of an injection mold, cooling the molten mixture, and removing the resultant molding from the mold.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260815 - Multiparticulates: Extrusion of a mix containing a pharmaceutically active agent can be achieved using a plasticising excipient in an amount sufficient to act as plasticiser and also act as lubricant, thereby avoiding the need for inclusion of a lubricant. The invention provides multiparticulates with controlled release properties, substantially free of lubricant.... Agent: Duane Morris LLP - Ny Patent Department

20080260816 - Particulate lipid pharmaceutical composition: A particulate lipid pharmaceutical composition comprises a particulate solid non-lipid carrier and an oil-in-water emulsion on the carrier. The emulsion comprises a dissolved or dispersed pharmacologically active agent. The oil-in-water emulsion is released from the carrier on contact with an aqueous media to form an oil-in-water emulsion in the media.... Agent: Nixon & Vanderhye, PC

20080260817 - Compositions for the treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist: The present invention provides a therapeutic composition comprising a COX-2 selective inhibitor or a prodrug thereof and an LTB4 receptor antagonist. A method is provided for the use of such composition in the treatment, prevention, or inhibition of inflammation, an inflammation-related disorder, pain, or a pain-related disorder.... Agent: Pharmacia Corporation Global Patent Department

20080260818 - Controlled absorption of statins in the intestine: The present invention provides a controlled absorption formulation in which modified release of active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient into the body of the subject than can be achieved from the currently used... Agent: Winston & Strawn LLP Patent Department

20080260819 - Sustained release compositions of drugs: A sustained release pharmaceutical composition has been developed. The composition resists dose dumping when broken, crushed or chewed, which enhances the safety of the dosage form should it be accidentally or intentionally physically compromised. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080260821 - Berry preparations and extracts: A method for deriving compositions having antioxidant and anti-inflammatory activity from berries is provided. The method results in a berry extract compositions having stable anthocyanin content. In one aspect, the method comprises exposing a berry to a solvent composition having a pH of from about 1 to about 4.5, and... Agent: King & Schickli, PLLC

20080260820 - Oral dosage formulations of protease-resistant polypeptides: Oral dosage formulations of the protease-resistant therapeutic polypeptides are provided. The dosage formulations for administration per dosage per day or per week are higher than the subcutaneous dosage. Included among the oral dosage formulations are tablets and capsules, including enteric-coated forms. Methods for treatment or prevention of diseases or conditions... Agent: Bell, Boyd & Lloyd LLP

20080260822 - Synthesis of human secretory iga and igm and the formation of a medicament therefrom: A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080260823 - Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea: The invention provides an orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate for treating sialorrhea, as well as a kit comprising the orally disintegrating tablet, prescribing information, and a container. The invention also provides a method of treating sialorrhea in a patient comprising administering the orally disintegrating tablet... Agent: Leydig Voit & Mayer, Ltd

20080260824 - Bioadhesive rate-controlled oral dosage formulations: The present invention relates to a bioadhesive drug delivery system (BIOadhesive Rate controlled Oral Dosage (BIOROD) formulation) in which a drug containing core either alone or coated with a rate controlling membrane system is enveloped on its circumference by a bioadhesive coating, thereby yielding a monolithic system that allows for... Agent: Ropes & Gray LLP

20080260825 - Methods and compositions for reduction of side effects of therapeutic treatments: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a... Agent: Wilson Sonsini Goodrich & Rosati

20080260826 - Pharmaceutical composition and process: The present invention relates to a method of forming granules of (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl isobutyrate; hydrochloride salt (I), comprising mixing I, with a granulating amount of a granulating liquid, and a polyethylene glycol (PEG)/polypropylene glycol (PPG) block copolymer as a binder and solubility enhancer to form wet granules which are then dried... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080260827 - Risedronate compositions and their methods of use: A method comprising orally administering to a human or other mammal a pharmaceutical composition comprising from about 65% to about 110% of the cumulative effective dose of risedronate or a pharmaceutically acceptable acid, salt, ester, solvate, or polymorph thereof according to a continuous dosing schedule of one, two, or three... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080260828 - Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it: This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30,000.... Agent: Buchanan, Ingersoll & Rooney PC

20080260829 - Bmp gene and fusion protein: This invention relates to BMP fusion genes, BMP fusion proteins. The invention further relates to methods for treatment using BMP fusion genes and BMP fusion proteins. Additionally, the invention relates to BMP fusion gene and BMP fusion protein pharmaceutical compositions.... Agent: Darby & Darby P.C.

20080260831 - Extracellular matrix-derived gels and related methods: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which... Agent: Jesse A. Hirshman, Esq.

20080260830 - Growth factor mutants with improved biological activitiy: The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080260833 - Drug delivery vehicle containing vesicles in a hydrogel base: A drug delivery vehicle having active agent loaded vesicles in a hydrogel matrix; desirably either or both of the vesicles and matrix are made of at least one stimulus responsive polymer so that active agent is released in response to contact with a stimulus.... Agent: Law Office Of Collen A. Beard, LLC

20080260832 - Sustained release intraocular implants and methods for preventing retinal dysfunction: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable... Agent: Allergan, Inc.

20080260834 - Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders: Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080260835 - Pharmaceutical compositions for poorly soluble drugs: The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may... Agent: Birch Stewart Kolasch & Birch

20080260836 - Films comprising a plurality of polymers: Films are disclosed that comprise a first polymer and a second polymer having a solubility temperature lower than that of the first polymer; wherein the breaking strength of the film is greater than about 750 psi (5,171 kPa). Also disclosed are compositions comprising such films that are useful as oral... Agent: Colgate-palmolive Company

20080260837 - Physically stable aqueous suspensions of active pharmaceuticals: The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides an aqueous pharmaceutical suspension composition comprising an active pharmaceutical component which is sparingly soluble to insoluble in water; a water soluble, low viscosity grade cellulose... Agent: Roberts & Roberts, LLP Attorneys At Law

20080260838 - Glucagon-like peptide 1 (glp-1) pharmaceutical formulations: A composition is disclosed comprising glucagon-like peptide 1 (GLP-1) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080260841 - Micronized wood preservative formulations: The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080260839 - Pulmonary formulation: The use of microparticles of silicon and particularly resorbable and/or photoluminescent silicon in the preparation of a medicament for nasal or pulmonary delivery. Aerosol formulations and their preparation are also described and claimed. These formulations may be used for example as carriers for pharmaceutical compounds as well as having diagnostic... Agent: Nixon & Vanderhye, PC

20080260840 - Suspension formulations of insulinotropic peptides and uses thereof: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic... Agent: Intarcia Therapeutics, Inc. Attn: Barbara G. Mcclung

20080260842 - Permeation enhancing compositions for anticholinergic agents: A transdermal or topical skin-friendly composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.... Agent: Winston & Strawn LLP Patent Department

20080260843 - transpulmonary composition: It is an object of the present invention to provide a transpulmonary preparation wherein physiologically active ingredient can be stably retained and which has high absorption efficacy and gives low damage to tissue. The present invention provides a transpulmonary preparation which comprises protein nanoparticles containing an active ingredient and having... Agent: Sughrue Mion, PLLC

20080260844 - Solid, oral, microparticulate dosage form which has been designed to prevent misuse: The invention relates to the field of solid, oral, microparticulate dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient contained therein. The aim of the invention is to prevent the improper use of solid oral medicaments for any use other than the therapeutic use(s) officially... Agent: Patton Boggs LLP

20080260845 - Multiple active drug resin conjugate: A combination pharmaceutical preparation including two different active drugs of the same ionic charge conjugated with a single resin particle, without one significantly displacing the other, and without retarding the initial availability of either active. Also, methods for the manufacture of a multiple active drug-resin conjugate, and for the in... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080260846 - Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof: The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically... Agent: Stetina Brunda Garred & Brucker

20080260849 - Composition for transmucosal absorption: It is an object of the present invention to provide a composition for transmucosal absorption which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high transmucosal absorbability. The present invention provides a composition for transmucosal absorption which comprises protein nanoparticles containing an active... Agent: Sughrue Mion, PLLC

20080260848 - Compositions that enable rapid-acting and highly absorptive intranasal administration: Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs.... Agent: Wilson Sonsini Goodrich & Rosati

20080260847 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080260850 - Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative: Delivery system for bioactive agents on the basis of a polymeric drug carrier formed from compositions comprising an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block having a terminal hydroxyl group substituted with a tocopherol or cholesterol group, and a polylactic acide derivative wherein one end of... Agent: LexyoumeIPGroup, LLC

20080260851 - Polymeric nanoparticles and nanogels for extraction and release of compounds: The invention relates to polymeric nanoparticles and nanogels, which can contain, deliver, and/or release one or more active agents, such as biologically active molecules or fragrance molecules, and methods of preparing the polymeric nanoparticles and nanogels. The nanoparticles are crosslinked utilizing radiation (g-radiation) as the catalyst for free radical polymerization... Agent: Schwegman, Lundberg & Woessner, P.A.

20080260852 - Supercritical fluid extraction produced by in-line homogenization: A method for producing micro and/or nanoparticles by contacting an emulsion with a supercritical fluid. The method can be used to produce an aqueous suspension of particles that include a drug encapsulated in a polymer. The drug and polymer are dissolved in an organic solvent to form an organic solution.... Agent: Rankin, Hill & Clark LLP

20080260853 - Extracellular matrix as surgical adjunct in a lumpectomy procedure: The invention an article or composition of mammalian extracellular matrix (ECM) for placement in a lumpectomy space of a breast after tumor removal. The extracellular matrix article or composition can regenerate lost breast tissue, reduce the formation of scar tissue at the site of excision, and reduce a likelihood of... Agent: Leigh Hunt Firestone

20080260854 - Sirna molecules for the treatment of blood vessels: The present invention relates to a nucleic acid molecule, a genetic construct, siRNA molecules and a composition which comprises the nucleic acid molecule and/or the genetic construct and/or the siRNA molecules and can be used for inhibition of the expression of endothelial adhesion molecules. The invention also relates to a... Agent: Klarquist Sparkman, LLP

20080260855 - Processed water and therapeutic uses thereof: A physiologically ingestible composition of matter obtained by preparing oxygenated water with a stable negative oxidation reduction potential (ORP), and the uses thereof, are provided. The obtaining method includes preconditioning water received from a water source for electrolysis, performing electrolysis on the preconditioned water, outputting alkaline water and/or acidic water... Agent: Rene A. Vazquez Williams Mullen

20080260857 - Substance and method for treating neoplasms: The invention relates to substance and method for treating neoplasms in mammals. A substance for treating neoplasm comprises water comprising from 99.76 to 99.99 molecular % of light isotopologue 1H216O and up to 100% of residual isotopologues. A method for treating neoplasm comprises a step of administering to a mammal... Agent: Notaro And Michalos

20080260856 - Topical composition containing sacred water: Topical compositions having as at least one part of their composition sacred and/or holy water. These compositions are useful for imparting a spiritual sense of well-being.... Agent: The Halvorson Law Firm

20080260858 - Universal procoagulant: A thromboplastin reagent comprises: (i) activated sTF, (ii) a metal-chelating lipid, (iii) a metal ion, and (iv) a phospholipid. Activated sTF preferably includes the extracellular domain of TF and an oligohistidine moiety having at least 2 histidine residues, more preferably 2-10 histidine residues. Preferably, the histidine residues are consecutive. Attaching... Agent: Evan Law Group LLC

20080260859 - Composition containing omega-3 fatty acids and omega-6 fatty acids: A composition comprises at least an omega-3 fatty acid, at least an omega-6 fatty acid, and zinc. The composition is advantageously administered to a subject suffering from a condition of dry eye. In certain embodiment, the amount of omega-3 fatty acid is much higher than that of the omega-6 fatty... Agent: Bausch & Lomb Incorporated

20080260860 - Method for the acaricidal finishing of textile materials: The use is described of zinc pyrithione for finishing woven and non-woven textiles to render them resistant against colonization by house dust mites. Zinc pyrithione is used alone or in combination with other actives with or without other textile chemicals. The formulations comprising zinc pyrithione are applied to the textiles... Agent: Nixon Peabody, LLP

20080260861 - Modulating lymphatic function: Methods and compositions for modulating lymphatic function, e.g., by altering NO levels, are disclosed.... Agent: Fish & Richardson PC

20080260862 - Composition for treatment and prevention of bone loss: The composition set forth provides for the prevention and treatment of bone loss and osteoporosis. The formulation combines Vitamin D; Calcium Citrate Malate; Potassium Citrate; Magnesium; Boron and Vitamin K. Each component has an effect on its own combined with a synergistic effect with the other components.... Agent: Hoffman, Wasson & Gitler, P.C.

20080260863 - Compositions for mucociliary clearance and methods for administering same: Sterile, preservative-free premeasured hypertonic saline solutions may be administered to individuals afflicted with cystic fibrosis to increase mucolciliary clearance and to improve lung function. In particular, a 7% hypertonic saline solution may be administered at least 2 times a day, using a jet and/or vibrating-mesh nebulizer to an individual afflicted... Agent: Mcguirewoods, LLP

20080260864 - Topical compositions for the treatment of depilation-induced irritation or prevention thereof: The present invention relates to topical compositions comprising as active ingredients Aluminium Chloride and Sulfur for treatment of skin irritation induced by depilation. Said compositions have pharmaceutical and/or cosmetic and/or quasi cosmetic properties. The present invention also involves methods of making and methods of using such compositions. Furthermore, the present... Agent: Moore & Van Allen PLLC

20080260865 - Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite: Methods for treating bacterial respiratory tract infections in an individual comprise administering a therapeutic amount of nitrite composition having a pH of less than 7, and in specific embodiments, a pH of about 5.5-6.5, to the individual. The individual may be a pulmonary disease diagnosed individual and/or the infection may... Agent: Seed Intellectual Property Law Group PLLC

20080260866 - Method for decreasing inflammation and stress in a mammal: The present invention is directed to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080260867 - Hair growth stimulants and the manufacturing method thereof: A hair growth stimulant having excellent hair growth stimulation and hair growth effects without any side effects, which contains a carbonized pine cone. The inventive hair growth stimulant has an excellent hair growth stimulation effect without causing any side effects or toxicity to the human body, while it can stimulate... Agent: Iphorgan, Ltd.

20080260868 - Folate based composition for neurological and cognitive applications: New formulations for the prevention and treatment of neurological diseases and cognitive deficiencies, particularly Alzheimer's Disease comprise folate in combination with compounds chosen to address some or all of the pathways which can result in neurological deficiencies and diseases, namely inflammation, oxidative stress, glycation/dysinsulinemia, platelet function, homocysteine levels and acetylcholinesterase... Agent: Venable LLP

20080260869 - Magnolia extract containing compositions: Disclosed is a composition comprising at least two of the following ingredients: Magnolia extract, honokiol, humulus lupulus extract, hesperidin methyl chalcone, gotu kola, dipeptide valyl-tryptophane, palmitoyl tetrapeptide-3, corylus avellana bud extract, centella asiatica extract, cucumis sativa extract, morus alba extract, hibiscus sabdariffa flower extract, vitis vinifera extract, ascorbyl glucoside, citrus... Agent: Fulbright & Jaworski L.L.P.

20080260870 - Compositions for protecting liver, or for preventing or treating liver fibrosis or cirrhosis: Disclosed is a composition for hepatoprotection, or for prevention or treatment of liver fibrosis or cirrhosis, which comprises as an active ingredient a water extract of a mixture of Trionycis Carapax, Raphani Semen, Artemisia capillaris Herba, Atractylodis Macrocephalae Rhizoma, Poria cocos, Alismatis Rhizoma, Atractylodis Rhizoma, Salvia Miltiorrhizae Radix, Polyporus, Amomi... Agent: Lee, Hong, Degerman, Kang & Schmadeka

20080260872 - Gro-protect solutions: Gro-Protect Solutions is applied to the natural hair (wherever gluing products will be applied) It is recommended that the natural hair is completely dry before applying Gro-Protect Solutions. Once Gro-Protect Solutions is applied to the natural hair it needs to be dried underneath a heated dryer (it can also dry... Agent: Calvin Lee Garris

20080260871 - Method and composition for infusing herbal extracts and pharmaceuticals through the skin: A topical mixture, that when massaged onto the skin, enables infusion of drugs or herbal compounds into deeper tissues, and a method of enhancing the penetration and concentration of drugs and herbs into tissues, especially as relates to treatment of pain.... Agent: Snell & Wilmer L.L.P. (main)

20080260873 - Agent for prevention or improvement of neuropathy comprising pre-germinated brown rice lipid fraction as an effective ingredient: t

20080260875 - Novel skin care compositions and methods: Skin care compositions and methods are provided comprising a highly hydrophobic substance, an alkaryl polyfluorocarbon, particularly a substituted phenyl-polyfluoroacylamino propanamide, an alkanol and refined oils and the oil triglyceride fractions in sufficient amount to provide substantial homogeneity. When employed for hirsutism, optionally antioxidants and moisturizer are added. For use against... Agent: Peters Verny , L.L.P.

20080260874 - Peripheral blood flow-improving composition: The present invention provides a composition that can effectively improve peripheral blood flow to thereby ameliorate cold sensation, numbness, pains and other skin symptoms, as well as frostbites, chilblains and chaps and other skin disorders associated with disturbed peripheral blood flow. This composition has no side effects. Specifically, the peripheral... Agent: Drinker Biddle & Reath (dc)

20080260876 - Garlic extract compositions, uses and preparations thereof: The present invention relates to compositions comprising a garlic extract and chitosan or a salt thereof. These compositions present an enhanced antifungal activity, or activity for controlling powdery mildew disease, in various types of plants, vegetables, fruits or flowers, particularly when compared to garlic extract alone or to chitosan or... Agent: Ogilvy Renault LLP

20080260877 - Plant extracts and compositions for reducing blood lipid levels: An extract of a plant of the genus Gynostemma is described. The extract is obtainable by a process wherein an aqueous extract is further extracted with n-butanol. The extract has a high level of actives, such as saponins, and/or a low level of impurities. The extract is particularly suitable for... Agent: Unilever Patent Group

20080260878 - Composition for prevention or alleviation of pigmentation: A composition for the prevention or alleviation of pigmentation which can produce the higher effect of preventing or alleviating pigmentation. The composition for the prevention or alleviation of pigmentation comprises a combination of (A) at least one member selected from the group consisting of adenosine 5′-monophosphate and salts thereof with... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260879 - Use of paeonia and extracts thereof with growth promoting activity in veterinary medicine and zootechnics: The present invention relates to the use of extracts of plants or roots of the Paeonia genus, in particular Paeonia lactiflora, for the preparation of growth promoters for use in livestock.... Agent: Young & Thompson

20080260880 - Oral compositions for the prevention of uv damages: The invention relates to oral compositions for the prevention of UV damages, in particular to oral compositions based on an olive extract obtained by extracting vegetation water from olive pressing with an organic solvent or by extracting olive cake with water and/or an organic solvent.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20080260881 - Blue-green algae composition: A broad spectrum functional food formulation based on blue-green algae and concentrated extracts of blue-green algae provides numerous health benefits when orally administered in therapeutically effective amounts. Whole aphanizomenon flos-aqua is combined with concentrates of phycocyanin and phenylethylamine to provide a life-enhancing dietary supplement which can stimulate stem cell production,... Agent: Lawrence J. Shurupoff

20080260635 - Cytotoxicity mediation of cells evidencing surface expression of mcsp: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.A.

20080260634 - Diagnostic use of endothelin etb receptor agonists and eta receptor antagonists in tumor imaging: Methods of imaging tumors are disclosed. The methods utilize an endothelin ETB receptor agonist or an endothelin ETA receptor antagonist, in combination with an imaging agent, to detect a tumor in mammals, including humans.... Agent: Marshall, Gerstein & Borun LLP

20080260636 - Stabilization of radionuclide-containing compositions: Described are methods for stabilizing radionuclide-containing compositions against degradation caused by free radicals generated from the radionuclide. Iodide ions stabilize the radionuclide-containing compositions by acting as scavengers to generated free radicals, thus, preventing or lessening degradation therefrom. Among the preferred radionuclide-containing compositions to be stabilized are complexes of a complexing... Agent: Millen, White, Zelano & Branigan, P.C.

20080260637 - Methods of detecting prostate cancer: A method of detecting presence or absence of prostate cancer in a subject, both in vivo and ex vivo is disclosed. The method comprises analyzing mitochondria or a mitochondrial component in at least one prostate cell of the subject, whereby mitochondria an alteration in quantity and or characteristic is indicative... Agent: Martin D. Moynihan Prtsi

20080260639 - Preparation and method utilizing radiolabeled chlorotoxin: The inventors propose to label a chlorotoxin with I-123 or I-124 for a diagnostic agent, and with I-124 or I-131 for a therapeutic agent to reduce tumors and then to use a process they previously invented to stabilize the radiopharmaceutical. The inventors propose to reconstitute the preferred agents and administer... Agent: Brooke Schumm Iii Daneker, Mcintire, Schumm, Prince, Goldstein Et Al

20080260638 - Receptor(sstr2)-selective somatostatin antagonists: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4... Agent: Fitch Even Tabin And Flannery

20080260642 - Bacteriophage-based contrast agents, the use thereof and a method for the production thereof: Bacteriophage-based contrast agents and a method for the production thereof are disclosed. The bacteriophages, in at least one embodiment, contain a first fusion protein comprising a phage-surface protein and a ligand specific for an identifiable target structure and a second fusion protein comprising a phage-surface protein and a peptide binding... Agent: Harness, Dickey & Pierce, P.L.C

20080260641 - Human monoclonal antibodies against cd20: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080260640 - Use of precursors of tachykinins and/or their fragments in medical diagnostic: The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other biological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of... Agent: Heslin Rothenberg Farley & Mesiti PC

20080260644 - Chloride transport upregulation for the treatment of traumatic brain injury: Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.... Agent: Dann, Dorfman, Herrell & Skillman

20080260645 - Method and use of cold-pressed botanic seed oils for lowering blood pressure and ldl cholesterol: m

20080260643 - Use of pde7 inhibitors for the treatment of movement disorders: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080260646 - Imaging reporters of transgene expression: Disclosed are compositions and methods for imaging in animals.... Agent: Morgan, Lewis & Bockius LLP (sf)

20080260648 - Pharmaceutical preparation containing magnetic vesicular particles, manufacturing method thereof and diagnostic therapeutic system: s

20080260649 - Method of dynamic nuclear polarisation dnp: The invention relates to a method of dynamic nuclear polarisation (DNP) using a combination of a trityl radical and a paramagnetic metal ion as the polarising agent leading to enhanced levels of polarisation in the sample to be polarised and to compositions and polarising agents for use in the method.... Agent: Ge Healthcare, Inc.

20080260650 - Methods of detection and therapy of inflamed tissues using immune modulation: The present invention relates to methods for the detection and therapy of inflamed tissue, whereby immune modulators are used to increase the uptake of diagnostic or therapeutic compositions by inflammatory cells.... Agent: Ewards Angell Palmer & Dodge LLP

20080260651 - Contrast agents: e

20080260647 - Method for fluorescence tomographic imaging: There is provided a method for determining the concentration of a fluorophore in a medium using moments of order k of the fluorescence signal. The method allows higher fidelity 3-dimensional reconstructions of the fluorophore in the medium. The method can be applied in imaging of fluorophores in biological tissues.... Agent: Bereskin And Parr

20080260652 - Composition for dyeing dental plaque for evaluating dental caries activity: An objective of the present invention is to provide a composition for dyeing dental plaque for evaluation of dental caries activity that is capable of simultaneously dyeing dental plaque and evaluating dental caries activity, and which can evaluate thick dental plaque more accurately than the conventional technique. The composition for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260655 - Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses: The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further... Agent: Wilmerhale/boston

20080260654 - Sustained release composition of protein drug: Disclosed is a sustained release composition of a protein drug. The composition comprises a carrier substrate and a protein drug incorporated in the carrier substrate. The carrier substrate is consisting essentially of a hyaluronic acid or its salts, an amino acid, and a polyalkyl oxide.... Agent: Cantor Colburn, LLP

20080260653 - Transdermal delivery systems and transdermal chelation preparations: The invention provides topical chelating preparations and formulations. The invention provides methods of transepithelial delivery of a topical chelating preparation to a human or other animal by topical application to the skin of a human or animal of a topical chelating preparation. In one aspect, a preparation or formulation of... Agent: Morrison & Foerster LLP

20080260656 - Ungual/periungual compositions comprising morpholine compounds and water-soluble film-forming agents: Pharmaceutical compositions suited for ungual and periungual application and useful for the treatment of dermatological conditions/afflictions, in particular onychomycosis, contain an anti-mycotic agent of the family of the morpholines and a water-soluble film-forming agent.... Agent: Buchanan, Ingersoll & Rooney PC

20080260657 - Process for milling poorly soluble drugs in presence of liquid propellants: Drug substance for use in a pharmaceutical formulation may be prepared by a process which process comprises co-milling a suspension of the drug substance and a pharmaceutically acceptable polymer in a liquid propellant.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080260659 - Compositions: The invention is directed to personal care products and compositions that comprise at least one preservative compound selected from the group consisting of benzoic acid, p-hydroxy-benzoic acid, methyl-paraben, ethyl-paraben, propyl-paraben, isopropyl-paraben, butyl-paraben, isobutyl-paraben, benzyl-paraben, or a salt thereof, in a total concentration of 0.1% to 0.5% (w/w); and at least... Agent: Norris, Mclaughlin & Marcus

20080260658 - Hair setting compositions based on t-butyl acrylate and hydroxyalkyl methacrylate: The present invention relates to copolymers, which comprises, in copolymerized form, between 25 and 80% by weight of tert-butyl (meth)acrylate, 2 to 60% by weight of hydroxyalkyl (meth)acrylate, 10 to 40% by weight of an anionic or anionogenic, free-radically polymerizable, olefinically unsaturated compound which is or comprises methacrylic acid, and,... Agent: Connolly Bove Lodge & Hutz, LLP

20080260660 - Teeth whitening agents: The invention relates to light-activated teeth whitening compositions, and to the use thereof for lightening teeth. The inventive whitening agent contains riboflavin and or the derivatives thereof, which enable the oxidant in the whitening agent to decompose more rapidly, by means of radiation energy, thus effectively accelerating the whitening action.... Agent: Edwards Angell Palmer & Dodge LLP

20080260661 - Aminobutadiene-based uv screens: The invention relates to the use of an UV-absorbing compound for the preparation of a cosmetic composition for protection against UV radiation said compound being represented by the general formula (I) wherein less than 10% of the total absorption between 250 and 600 nm of said UV-absorbing compound according to... Agent: Foley And Lardner LLP Suite 500

20080260663 - Esterification reaction products and cosmetic products: e

20080260662 - Sunscreen compositions comprising carotenoids: The invention concerns methods of treating or preventing the effects of irradiation in a human or non-human animal using carotenoid compounds, preferably diadinoxanthin, diatoxanthin and/or fucoxanthin as well as photoprotective compositions and their use to prepare photoprotective or photoprotected products.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080260664 - Particles functionalized with organic compounds: The present invention relates to particles comprising an inorganic network and organic compounds covalently bonded to the network via a spacer group, where the organic compounds are present in the interior of the particles and optionally also on the surface of the particles. The present invention furthermore relates to processes... Agent: Millen, White, Zelano & Branigan, P.C.

20080260665 - Nail varnish comprising at least one polycondensate and at least one polyoxyalkylene copolymer: copolymers comprising at least one polyethylene glycol block and at least one polypropylene glycol block, the said copolymer exhibiting a molecular weight of greater than or equal to 1000 g/mol and their mixtures.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260666 - Cosmetic compositions comprising at least one non-ionic surfactant and at least one vinylamide/vinylamine copolymer and methods of use thereof: p

20080260667 - Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin:

20080260668 - Method for preparing a compound for drawing a non-permanent tattoo and a method of using said compound: The present invention refers to a method for preparing of a compound for drawing a non-permanent tattoo from the “jenipapo” fruit (Genipa americana). A certain amount of juice from the “jenipapo” fruit (Genipa americana) is provided, into which a thickener is added for forming a substantially creamy compound, which receives... Agent: Ronald R Santucci Frommer Lawrence Haug LLP

20080260669 - Aromachemicals: wherein R1 and R2 represent, independently, linear or branched C1-4 alkyl, n=0 to 4 and m=0 to 3. Mixtures of these compounds, methods for their preparation, their use as perfume materials for application to a variety of substrates and their use in flavouring and in articles of manufacture is also... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080260670 - Organic compounds: e

20080260672 - Aqueous preservative solution with high amino acid content: Aqueous preservative solutions with a high amino acid content which is excellent in preservation, particularly a preservative effect on fungi, and safety, and is excellent in storage stability so as not to cause a problem such as depositing, coloring or smelling even when it is stored for a long time,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260671 - Depilatory compositions: A depilatory composition comprising a depilatory compound having a thiol group and a quinone and/or phenol compound.... Agent: Merchant & Gould PC

20080260674 - Cosmetic use of amphoteric polysaccharide compounds containing cationic polymer chain (s): The invention relates to the cosmetic use, especially for the cosmetic treatment of keratin materials, of amphoteric polysaccharide compounds containing cationic polymer chain(s), which may be obtained by grafting and polymerization of ethylenic monomers of formula (I), Q− onto an anionic polysaccharide of formula (II): in the presence of a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260675 - Depolymerized scleroglucan for regulating and improving the moisture content of the skin: The use of depolymerized scleroglucan alone, or in combination with one or more active ingredients as a moisturizer, and as anti-inflammatory active ingredient for protecting and for restoring a healthy skin barrier in the field of cosmetic or dermatological skincare is disclosed.... Agent: Scully Scott Murphy & Presser, PC

20080260673 - Conditioning composition: The present invention is related to composition for conditioning keratin fibres especially human hair with reduced bulk density. The inventors of the present invention have found out that a conditioning composition comprising at least one shear thickening polymer and at least one conditioning compound and having reduced bulk density solves... Agent: Norris, Mclaughlin & Marcus, P.A.

20080260676 - Hydroxycucurbituril derivatives, their preparation methods and uses: Provided are hydroxycucurbituril derivatives, their preparation methods and uses. The hydroxycucurbituril derivative is easy to further functionalize with enhanced solubility in common solvents, thereby providing wider applications.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080260677 - Transdermal topical composition and its uses: An emollient component is provided in a composition, suitable for topical application to skin, comprising a fugitive solvent base comprising at least one alcohol. One advantage of the invention is that the irritancy potential of the composition due to the alcoholic fugitive solvent base is reduced.... Agent: Catalyst Law Group, Apc

20080260679 - Methods and compositions for treatment of ion imbalances: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment... Agent: Senniger Powers LLP

20080260678 - Molecular band-aid: A molecular sealant comprising a therapeutically effective amount of a poloxamer capable of sealing a cell or tissue from leaks. A method of treating tissue leakages by applying the above sealant to the tissue or cell in need of treatment. A composition for treating cellular leakages comprising a poloxamer capable... Agent: Warner Norcross & Judd LLP

20080260680 - Method of attenuating reactions to skin irritants: The present invention is directed to a method of inhibiting CDld activation by administering a composition containing a moiety that blocks CDld activation. Compositions of the invention are useful for the attenuation of CDld-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for... Agent: Wilson Sonsini Goodrich & Rosati

20080260681 - Compositions and methods for treating and preventing cardiomyopathy and heart disease: The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188-P1 88) and methods of using the same for treating and preventing heart disease (e.g., in subjects with muscular dystrophy) and for treating cells and... Agent: Tyler J. Sisk Casimir Jones

20080260682 - Polyethylene glycol colonic purgative composition: This invention relates to novel colonic purgative compositions of polyethylene glycol having an average molecular weight of at least 1,000 or at least 4,000. Further, this invention relates to methods of using the colonic purgative compositions. The formulations and methods of this invention are particularly useful to cleanse the bowel... Agent: Edwards Angell Palmer & Dodge LLP

20080260683 - Rodenticide: The invention relates to the systemic insecticide fipronil in conjunction with a rodenticide used for manufacture of a bait composition to provide a lethal effect on fleas and/or ticks and a host rodent, following ingestion of the bait composition by the host rodent. Preferred rodenticides are brodifacoum, difethialone, flocoumafen, bromadiolone... Agent: Fish & Richardson PC

20080260684 - Method for the purification of g-csf: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying... Agent: Knobbe Martens Olson & Bear LLP

20080260685 - Prodrugs of cc-1065 analogs: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a... Agent: Sughrue Mion, PLLC

20080260686 - Methods of using il-31 to treat airway hyper-responsiveness and asthma: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness... Agent: Zymogenetics, Inc. Intellectual Property Department

20080260688 - Novel inhibitors of glutaminyl cyclase: e

20080260689 - Peptides for active anti-cytokine immunization: Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080260687 - Specific binding agents for kshv vil-6 that neutralize a biological activity: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds... Agent: Klarquist Sparkman, LLP

20080260690 - Interferon in influenza: The use of an interferon (IFN) for the manufacture of a medicament for treatment and/or prevention of influenza, preferably avian influenza, is described in the present invention.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080260691 - Prodrugs of ribavirin with improved hepatic delivery: The present invention relates ribavirin delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to ribavarin and methods for administering conjugated ribavirin compositions.... Agent: Darby & Darby P.C.

20080260692 - Spirulin composition rich in active principles, method for obtaining same and use thereof: The invention relates to a spirulina combination composed of at least two distinct strain types from the genus Arthrospira, particularly Arthrospira LONAR and Arthrospira PARACAS whose phycocyanin content is between 13 and 30%, a method for obtaining such a combination, a composition containing this combination, and its use as a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080260693 - Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (lcmv): The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.... Agent: Viksnins Harris & Padys Pllp

20080260707 - Isolated homozygous stem cells, differentiated cells derived therefrom and materials and methods for making and using same: The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed... Agent: Patton Boggs LLP

20080260705 - Preventing arrhythmias associated with cell transplantation: Skeletal myoblasts are an attractive cell type for transplantation since they are autologous and resistant to ischemia. However, clinical trials of myoblasts transplantation in heart failure have been plagued by ventricular tachy-arrhythmias and sudden cardiac death. The pathogenesis of these arrhythmias is poorly understood, but may be related to the... Agent: Banner & Witcoff, Ltd.

20080260706 - Transient transfection with rna: A method of mRNA production for use in transfection is provided, that involves in vitro transcription of PCR generated templates with specially designed primers, followed by polyA addition, to produce a construct containing 3′ and 5′ untranslated sequence (“UTR”), a 5′ cap and/or Internal Ribosome Entry Site (IRES), the gene... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080260694 - Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof: The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.... Agent: Cooper & Dunham, LLP

20080260695 - Composition for prevention and/or treatment of cancer: The invention relates to a composition for use in the prevention and treatment of cancer. The composition includes fermented soy extract, oligomeric proanthocyanidin, epigallocatiechin gallate, spirulina, curcumin and Antrodia camphorata. The composition of the invention effectively prevents the growth of cancer cells, especially colorectal cancer, ovarian cancer, breast cancer, cervical... Agent: Birch Stewart Kolasch & Birch

20080260696 - Method for decreasing inflammation and oxidative stress in mammals: The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to decrease a level of an oxidized glutathione and/or increase the... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080260708 - Methods and related systems and formulations to normalize and improve human body chemistry and healing ability: Methods, systems and formulations for normalizing and improving human body chemistry and the body's natural ability to heal itself. In one embodiment a system including effective amounts of a digestive enzyme, soluble and insoluble fiber, laxative, probiotics, vitamin C, potassium, protease enzymes, lipase, lysine, taurine, proline, choline, inositol, inositol hexaphosphate,... Agent: Greenberg Traurig LLP (la)

20080260709 - Cholesterol-lowering agents, secondary bile acid production inhibitors and foods and drinks: Secondary bile acid production inhibitors and cholesterol-lowering agents containing a yeast as the active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260697 - Bacterial management in animal holding systems: The present invention is directed to method for reducing a population of a target pathogen in an animal or within a feedlot. The method involves administering one or more than one controlled release bacteriophage strain or phage component, or both, to the animal, so that the one, or more than... Agent: Brinks, Hofer, Gilson & Lione

20080260698 - Chimeric sindbis-western equine encephalitis virus and uses thereof: The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment, an Eastern equine encephalitis virus cDNA fragment, a Western equine encephalitis virus cDNA fragment or a combination thereof. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays.... Agent: Benjamin Aaron Adler Adler & Associates

20080260699 - Adminstration of intact mammalian cells to the brain by the intranasal route: The present invention provides an intranasal method for delivery of intact mammalian cells to the brain for treatment of neurological deficits. This approach applies an intranasal instillation to directly administer cells to the brain, and is useful as therapy for patients with neurological deficit or those who may benefit from... Agent: Richard Aron Osman

20080260701 - Anti-angiogenic cellular agent for cancer therapy: The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When... Agent: Beyer Weaver LLP

20080260704 - Combination treatment of cardiovascular disease: Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.... Agent: Baumgartner Patent Law

20080260700 - Generation of pancreatic endocrine cells from primary duct cell cultures and methods of use for treatment of diabetes: The invention is directed to spontaneously immortalized pancreatic duct cells and methods for generating pancreatic endocrine cells from spontaneously immortalized pancreatic duct cells that express the transcription factors Pdx1 and FoxO1. The invention also provides for methods for treating beta cell failure, the method comprising administering to a subject an... Agent: Wilmerhale/columbia University

20080260703 - Treatment of insulin resistance and diabetes: Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular... Agent: Baumgartner Patent Law

20080260702 - Treatment of retinopathies using gfra3 agonists: The present invention relates to the use of GFRα3 agonists for the treatment of disorders of the retina. A preferred GFRα3 agonist is Neublastin. Neublastin may be administered to the eye using protein formulations, in vivo or ex vivo gene therapy, or implantation of encapsulated cells delivering Neublastin locally to... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080260710 - Method for suppressing surgical site infection and column to be used for the method: An object of the present invention is to provide a method for suppressing surgical site infections (SSI) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method.... Agent: Greenblum & Bernstein, P.L.C

20080260711 - Detoxifizyme with activity of transforming aflatoxin and the gene encodes thereof: The present invention relates to a detoxifizyme with the activity of transforming aflatoxin and the gene encodes thereof. Inventors firstly isolate and purify a novel protein, named aflatoxin-detoxifizyme (ADTZ), which has the activity of transforming aflatoxin. The primes specify to the ADTZ gene are obtained through purification and sequencing. The... Agent: Myers Dawes Andras & Sherman, LLP

20080260712 - Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability: A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize... Agent: Robert Berliner Berliner & Associates

20080260714 - Fibrin compositions containing strontium compounds: A composition for use in bone healing and bone regeneration in the form of a viscoelastic hydrogel gel or liquid formulation comprising fibrinogen, thrombin and an inorganic component comprising a strontium (Sr) containing compound and/or possibly another metal such as a calcium containing compound. The strontium containing compound can be... Agent: Howrey LLP - Dc

20080260713 - Neukinase, a downstream protein of neuregulin: The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies,... Agent: Jones Day

20080260715 - Precursor n-acetylgalactosamine-4 sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme: The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including... Agent: Marshall, Gerstein & Borun LLP

20080260716 - Method and composition for high level disinfection employing quaternary ammonium compounds: Methods and compositions for high level disinfection (as herein defined) of a surface. Methods include treating the surface with a composition including a quaternary ammonium compound in a concentration which exceeds 1% w/w and the temperature of treatment is in the range of from 30° C. to 80° C. A... Agent: Edwards Angell Palmer & Dodge LLP

20080260724 - Drug induced exposure of the fungal pro-inflammatory molecule beta-glucan: Methods and reagents for screening for anti-microbial agents are provided. Diagnostic tools for assessing treatment of fungal infections are provided. Antimicrobial substances including substances useful for the treatment of fungal infections are provided. In some embodiments, the substances have antigen unmasking activity. In some embodiments the substances have fungicidal activity... Agent: Proskauer Rose LLP

20080260719 - Edg: modulators of lymphocyte activation and migration: The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates... Agent: Klarquist Sparkman, LLP

20080260722 - Method for high efficiency survival/proliferation of human embyonic stem cells and human embryo survival in culture: The present invention provides a role for neurotrophins in hES cell survival and important new insights into the molecular mechanisms controlling the growth of these cells. Although previous studies identified growth factors that affect self-renewal of hES cells, the novelty of the present invention is the identification of factors that... Agent: Edwards Angell Palmer & Dodge LLP

20080260723 - Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one... Agent: Law Office Of John K. Pike, PLLC

20080260717 - Methods for reducing seizure-induced neuronal damage: This invention provides a method for treating a subject either during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure comprising administering to the subject, either during or soon after the seizure, a therapeutically effective amount of an... Agent: Cooper & Dunham, LLP

20080260721 - Nucleic acids encoding a mammalian raptor polypeptide and uses therefor: The present invention relates to isolated raptor nucleic acid molecules of mammalian origin (e.g., human) and complements, portions and variants thereof. Another aspect of the invention are isolated raptor polypeptides of mammalian origin and portions thereof, and antibodies or antigen binding fragments thereof that specifically bind a raptor polypeptide. The... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080260726 - Organic compounds: A method of identifying a substance suitable for use in inhibiting mucus hypersecretion that modulates the activity of a human cathepsin C gene or its gene product. The method involves combining a candidate substance with the human cathepsin C gene or its gene product and measuring the effect of the... Agent: Novartis Institutes For Biomedical Research, Inc.

20080260718 - Phospholipase c gamma modulation and uses thereof for management of pain and nociception: The present invention provides methods of preventing and treating pain, by modulating, e.g. inhibiting, the activity, function and/or expression of a PLCγ in a subject. The invention further relates to methods of identifying agents capable of modulating the activity and/or expression of a PLCγ, or capable of modulating binding of... Agent: Ladas & Parry LLP

20080260720 - Systems and methods for inhibiting metastasis: The present invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for inhibiting cancer metastasis by inhibiting G12 and G13 activity.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080260725 - Tag and target delivery system: A system for targeting dividing cells and delivering therapeutic agents to the targeted cells using a Tag nanoparticle. Each Tag nanoparticle comprises a nucleotide encoding a Tag, which is expressed only in dividing cells. The system optionally utilizes a microparticle to deliver Tag nanoparticles to cells. Therapeutic nanoparticles comprising therapeutic... Agent: Ratnerprestia

20080260732 - Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis: The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.... Agent: Howrey LLP-ca

20080260734 - Compositions and methods for characterizing, regulating, diagnosing, and treating cancer: The present invention relates to compositions and methods for characterizing, regulating, diagnosing, and treating cancer. For example, the present invention provides compositions and methods for inhibiting tumorigenesis of certain classes of cancer cells, including breast cancer cells and preventing metastasis. The present invention also provides systems and methods for identifying... Agent: Casimir Jones, S.c.

20080260733 - Humanized collagen antibodies and related methods: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic... Agent: Wilson Sonsini Goodrich & Rosati

20080260729 - Method of treating cancer comprising a vegf-b antgonist: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their... Agent: Scully Scott Murphy & Presser, PC

20080260727 - Modulation of nkg2d: The present invention relates to methods and compositions for treating or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells and/or NK cells, by modulating NKG2D.... Agent: Medlen & Carroll, LLP

20080260731 - Optimized antibodies that target cd19: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20080260735 - Transfer request (37 cfr 1.821(e)) humanised antibodies to the epidermal growth factor receptor: The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080260730 - Treatment of crohn's disease or psoriasis using anti-interferon gamma antibodies: The present invention provides a method of treating autoimmune diseases. In particular, it provides a method for the treatment of Crohn's disease or psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of an antibody against interferon γ.... Agent: Townsend And Townsend And Crew LLP

20080260728 - Treatment of severe multiple sclerosis: Methods of treating multiple sclerosis are disclosed.... Agent: Fish & Richardson

20080260737 - Combination of blys and/or april inhibition and immunnosuppressants for treatment of autoimmune disease: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment... Agent: Zymogenetics, Inc. Intellectual Property Department

20080260736 - Methods and compositions to regulate iron metabolism: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in... Agent: Clark & Elbing LLP

20080260738 - Single chain fc, methods of making and methods of treatment: The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080260740 - Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080260739 - Use of anti-mortalin 2 antibody and functional nucleic acid for cancer therapies: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific... Agent: Sughrue Mion, PLLC

20080260746 - Erythropoietin polypeptides and uses thereof: The present invention relates to EPO polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080260744 - G protein coupled receptors and uses thereof: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists)... Agent: Seed Intellectual Property Law Group PLLC

20080260743 - Means and methods for detecting methylated dna: The present application relates to a nucleic acid molecule having a nucleotide sequence encoding a bifunctional polypeptide comprising the DNA-binding domain of a protein belonging to the family of Methyl-CpG binding proteins (MBDs) and the Fc portion of an antibody. In addition, vectors and host cells which comprise said nucleic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260747 - Methods and materials relating to cd84-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of... Agent: Nuvelo, Inc

20080260741 - Preventive and/or therapeutic agent for cancer: As the results of intensive studies aiming at providing a gene targeting a cancer cell or a cancer tissue, novel nucleotide sequences showing increased expression in a cancer cell or a cancer tissue compared with normal tissues are identified. As the results of the subsequent studies, genes showing increased expression... Agent: Edwards Angell Palmer & Dodge LLP

20080260742 - Preventives/remedies for cancer: The present invention provides preventives/remedies for cancer and so on. Specifically, an antibody against a protein comprising the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 17, SEQ ID NO: 25, SEQ ID NO: 38... Agent: Edwards Angell Palmer & Dodge LLP

20080260745 - Targeted identification of immunogenic peptides: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific... Agent: James Remenick Novak Druce & Quigg, LLP

20080260748 - Methods for damaging cells using effector function of anti-dsc2 antibody: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides... Agent: Townsend And Townsend And Crew, LLP

20080260749 - Novel tetrahydropyridothiophenes: e

20080260750 - Polynucleotides encoding acetylcholine-gated chloride channel subunits of caenorhabditis elegans: The invention relates to novel polynucleotides which encode novel polypeptides that are acetylcholine-gated chloride channel subunits and immunogenic or acetylcholine-binding fragments thereof. The novel polypeptides may be used for identifying compounds that modulate the acetylcholine-gated chloride channels, e.g. for use as pesticides and antiparasitic agents. Methods for identifying compounds that... Agent: Smart & Biggar P.o. Box 2999, Station D

20080260751 - Methods and compositions for the modulation of immune responses and autoimmune diseases: The present invention relates to a regulation of inflammation and immune responses. The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an activator of RP105. The condition is typically associated with TLR-4 activation and cytokine production. Conditions addressed by the invention... Agent: Frost Brown Todd, LLC

20080260752 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary... Agent: Lowrie, Lando & Anastasi, LLP

20080260754 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Rigel Pharmaceuticals Inc.

20080260753 - Mouse models of crohn's disease and a method to develop specific therapeutics: Provided are compositions, transgenic animals and methods for screening and analyzing agents useful for treating inflammatory bowel diseases. Also provided are methods to treat inflammatory bowel disease, Crohn's disease and Blau syndrome.... Agent: Buchanan, Ingersoll & Rooney LLP

20080260756 - Peptide inhibitors of iaspp: The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide.... Agent: Marshall, Gerstein & Borun LLP

20080260755 - Proteolytically cleavable fusion proteins with high molar specific activity: The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260757 - Bispecific fusion antibodies with enhanced serum half-life: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080260758 - Universal gm-csf expressing bystander human k562 cell line: The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition.... Agent: Barnes & Thornburg LLP

20080260761 - Compositions, splice variants and methods relating to cancer specific genes and proteins: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of... Agent: Licata & Tyrrell P.C.

20080260762 - Hla binding motifs and peptides and their uses: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080260759 - Novel mite allergen: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or... Agent: Greenblum & Bernstein, P.L.C

20080260760 - Prostate-specific antigen-derived mhc class h-restricted peptides and their use in vaccines to treat or prevent prostate cancer: The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more... Agent: Evans & Molinelli, PLLC

20080260766 - Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti-hiv-1 prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention: e

20080260763 - High throughput proteomics: Methods to obtain expression systems and proteins in a high-throughput protocol by utilizing mixtures of cells cultured from those transformed with a desired nucleotide sequence permit rapid production of protein for use in arrays to assess activity. In one embodiment, the proteins (or peptides) in the array are assessed for... Agent: Fish & Associates, PC Robert D. Fish

20080260765 - Hpv dna vaccines and methods of use thereof: Human papillomavirus (HPV) infection is the etiological factor for cervical cancer. Provided are HPV vaccines that generate a humoral immune response to prevent new infection, as well as cell-mediated immunotherapy to eliminate established infection or HPV-related disease. HPV vaccines include nucleic acid sequences encoding HPV16 early proteins E6 and E7.... Agent: Foley Hoag, LLP (w/jhv)

20080260764 - Replikin peptides and uses thereof: The present invention provides isolated influenza peptides and nucleic acid sequences and methods of identifying said influenza peptides and nucleic acid sequences having a pattern of substitution of amino acids or nucleic acids in highly conserved Replikin and Replikin Scaffold sequences that is predictive of rapid replication and virulence. Methods... Agent: Kenyon & Kenyon LLP

20080260767 - Novel protein which can be used, in particular, for the in vitro isolation and prevention of legionella pneumophila infections: The invention relates to novel polynucleotides, including SEQ ID NO: 1 or parts or variants of the sequence, novel polypeptides encoded by the polynucleotides, expression vectors including the polynucleotides and host cells including the expression vectors. The polynucleotides and polypeptides can be used in the field of in vitro diagnosis... Agent: Young & Thompson

20080260768 - Streptococcus pneumoniae proteins and nucleic acid molecules: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.... Agent: Hunton & Williams LLP Intellectual Property Department

20080260769 - Polypeptides for oligomeric assembly of antigens: A system for expressing antigenic polypeptides in oligomeric form fuses the antigenic polypeptide to an oligomerisation polypeptide such that the oligomerisation polypeptide can interact with other oligomerisation polypeptides and bring multiple copies of the antigenic polypeptide into close proximity in the form of an oligomer. Expressing the polypeptides in oligomeric... Agent: Novartis Vaccines And Diagnostics Inc.

20080260770 - Use of tellurium compounds as adjuvants: Methods for enhancing the immune response of a subject to an immunoeffector, and methods of enhancing interleukin-12 production, which are effected by administering an amount of the immunoeffector and an effective adjuvanting amount of a tellurium-containing compound are provided. The enhanced immune response may be a cell-mediated or a humoral... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20080260772 - Extract from agaricus blazei murill capable of suppressing breast cancer: A food material capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer. An extract of Agaricus Blazei Murill comprising an ingredient capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer is provided. This ingredient can be a chromatographic main elution... Agent: Perkins Coie LLP

20080260771 - Prostate disorder(s) phyto-nutraceutical synergistic composition: A Phyto-nutraceutical composition for the prevention and treatment of prostate disorders is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effect.... Agent: Jose Olalde Rangel

20080260774 - Alpha-galactosyl ceramide analogs and their use as immunotherapies: wherein, n is 0 to 25; X is selected from O and S; R1 is selected from H, CH3, and phenyl, where phenyl is optionally substituted with H, OH, OCH3, F, CF3, phenyl, phenyl-F, C1-C6 alkyl, or C2-C6 branched alkyl; R2 is selected from OH and H; R3 is selected... Agent: Greenberg Traurig LLP (la)

20080260773 - Saccharide conjugate vaccines: The invention provides compositions comprising a combination of two or more monovalent conjugates, each of said two or more monovalent conjugates comprising a carrier protein comprising T cell epitopes from two or more pathogens conjugated to saccharide antigen. The invention also provides a multivalent conjugate comprising two or more antigenically... Agent: Novartis Vaccines And Diagnostics Inc.

20080260775 - New live virus vaccines: The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an... Agent: Myers Bigel Sibley & Sajovec

20080260776 - Preparation of salmonella broad-spectrum vaccines: The present invention relates to a pharmaceutical composition providing protective unity against a broad spectrum of Salmonella enterica serovars.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080260777 - Composition and method for controlling intestinal pathogenic organisms: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field strains of E. coli, Pseudomona aeruginosa, Aerobacter aerogenes, Salmonella enteritidis, Salmonella typhimurium, Salmonella agona, and Salmonella Kentucky. The antigen, composition can be used alone or in combination... Agent: Amin Hallihan, LLC

20080260778 - Method of vaccination against testicular bvdv infection: The methods of the invention relate to methods for preventing testicular infection by bovine viral diarrhea virus by immunizing susceptible male animals against infection.... Agent: Pharmacia & Upjohn

20080260779 - Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080260780 - Materials and methods relating to improved vaccination strategies: The invention provides novel vaccination strategies based on a prime-boost vaccination regiment. The inventors have determined improved ways of boosting an immune response in a patient previously primed or exposed to a plurality of epitopes. The improved method requires the epitopes in the boosting phase to be administered individually, i.e.... Agent: Foley And Lardner LLP Suite 500

20080260781 - Proteosome influenza vaccine: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080260782 - Mycobacterium avium subspecies paratuberculosis vaccines and methods of using the same: The invention relates to vaccine compositions composed of at least one Mycobacterium avium subspecies paratuberculosis (MAP) antigen, or attenuated or killed MAP for use in methods of immunizing a human against a MAP infection, preventing or treating a MAP infection, and preventing a human disease associated with a MAP infection.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20080260783 - Composition and method for controlling intestinal pathogenic organisms: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes naturally-occurring wild Salmonella enterica subspecies in O-serogroups B, C2 and D. Subspecies in O-serogroup B can include Salmonella typhimurium and/or Salmonella agona. Subspecies in O-serogroup C2 can include Salmonella... Agent: Amin Hallihan, LLC

20080260784 - Compositions and methods for modulating an immune response: The present invention provides a composition for suppressing an inflammatory immune response comprising the excretory/secretory (ES) component of Fasciola hepatica or a fraction thereof. The composition has particular utility in the treatment or prophylaxis of T cell mediated inflammatory immune responses, and in particular autoimmune disease. The invention further extends... Agent: Marshall, Gerstein & Borun LLP

20080260785 - Paroxetine compositions: The invention relates to pharmaceutical compositions having polymers that release paroxetine in a controlled manner for a prolonged or sustained period of time. An embodiment of the invention provides enhanced bioavailability controlled release pharmaceutical compositions comprising paroxetine or its pharmaceutically acceptable salts, which enables a reduction in its orally administered... Agent: Dr. Reddy's Laboratories, Inc.

20080260786 - Process for making encapsulated particles: Method for preparing an active-containing starch matrix and the free flowing, dry powder that results from such a process. The active ingredients can be released (deposited) onto a surface by normal triggering mechanisms, which include the action of a liquid or by friction or rubbing. The fixative systems described herein... Agent: National Starch And Chemical Company

20080260787 - Use of collagen in combination with oxygen- and ozone-releasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions: A medicament and a medication for the treatment of skin lesions are disclosed, which comprise collagen and an oxygen-carrying and releasing fluorinated hydrocarbon and, optionally and preferably additionally, ozone. Particularly, the invention relates to a kit for the topical administration of such a medicament on the damaged skin, as well... Agent: Pearne & Gordon LLP

20080260788 - Skin cleaning composition: The present invention describes a skin cleaning and disinfecting composition comprising an active component, wherein the active component comprises at least one alcohol, at least one halogen. The present invention also describes corresponding anti-bacterial, anti-viral and anti-fungal compositions, as well as a method of manufacturing same.... Agent: Greenberg Traurig LLP (la)

20080260789 - Insecticidal polypeptides and methods of use thereof: A family of insecticidal polypeptides expressed in the venom gland of spiders of the genera Atrax and Hadronyche have been described. Also included are polynucleotides and expression vectors encoding the polypeptides and insect viruses and cells expressing the polypeptides. Transgenic plants and insects expressing the insecticidal polypeptides are also described.... Agent: Johathan P. O''brien Miller, Canfield, Paddock And Stone, P.L.C

20080260791 - Injectable capsaicin: The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting... Agent: Davidson, Davidson & Kappel, LLC

20080260792 - Method to use therapeutic microencapsulation of embedding parathyroid live cells with theracyte: A method to use a therapeutic microencapsulation of embedding parathyroid live cells with a TheraCyte comprises the steps of: (1) containing the parathyroid live cells in −179° C. liquid nitrogen and then unfrozen for preparing the therapeutic microencapsulation; (2) embedding at least 4×105 parathyroid live cells in the TheraCyte to... Agent: Nikolai & Mersereau, P.A.

20080260790 - Plasmid enhancement agent for high intensity focused ultrasound treatment and use thereof: The present invention discloses a plasmid enhancement agent for high intensity focused ultrasound (HIFU) treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a nanometer-sized biocompatible solid. The present invention also discloses another plasmid enhancement agent for HIFU treatment, wherein, the... Agent: The Webb Law Firm, P.C.

20080260793 - Porous gelatin material, gelatin structures, methods for preparation of the same and uses thereof: The present invention relates to a porous gelatin material in the form of spherical particles with a continuous pore structure and cast, three-dimensional, porous gelatin structures. The invention also comprises methods for preparation of the porous gelatin materials and structures. The method for preparing the porous gelatin material in the... Agent: Morgan Lewis & Bockius LLP

20080260798 - Aligned scaffolds for improved myocardial regeneration: The present invention relates to a biocompatible, three-dimensional scaffold useful to grow cells and to regenerate or repair tissue in predetermined orientations. The scaffold is particularly useful for regeneration and repair of cardiac tissue. The scaffold contains layers of alternating A-strips and S-strips, wherein the A-strips within each layer are... Agent: Fulbright & Jaworski L.L.P.

20080260799 - Bioactive implant and method of use: The invention relates to a method for producing bioactive implant surfaces consisting of metallic or ceramic materials, to be used for implants such as artificial joints or very small implants such as so-called stents. The invention also relates to implants produced according to this method and methods of using the... Agent: Foley & Lardner LLP

20080260794 - Collagen products and methods for producing collagen products: Medical implants and methods for forming a medical implant blends a dispersion of human collagen fibers and/or threads and optionally a volume between about 2 to about 15% of an alcohol and forms medical implants by removing a liquid component of the collagen dispersion. Medical implants formed include collagen films,... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080260797 - Methods of treating disease with nitric oxide (no)-releasing polymers and soluble no-releasing nitrosamines: The invention provides NO-releasing polymers and low molecular weight NO-releasing compounds which may be used to for the treatment of medical conditions associated with NO-deficiency. The NO-releasing polymers or the low molecular weight NO-releasing compounds may also be incorporated into medical devices. The invention further provides methods of controlled release... Agent: Michael Best & Friedrich LLP

20080260796 - Reduction of infection associated with medical device: Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.... Agent: Campbell Nelson Whipps, LLC

20080260795 - Strong reversible hydrogels: The present invention relates to improved hydrogel materials using water gellants that are comprised of polymer backbones P to which hydrogen bonding 4H-units are covalently attached via a hydrophobic linker L. Optionally, the hydrogel contains additional ingredients or additives. These new reversible hydrogels can easily be fine-tuned in their mechanical... Agent: Foley And Lardner LLP Suite 500

20080260800 - Extracellular matrix cancer vaccine adjuvant: Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described... Agent: Bell, Boyd, & Lloyd LLP

20080260802 - Biocompatible hydrogels made with small molecule precursors: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable, or not, are provided,... Agent: Dardi & Associates, PLLC

20080260801 - Composite material, especially for medical use, and method for producing the material: o

20080260803 - Sustained release intraocular inplants containing tyrosine kinase inhibitors and related methods: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix... Agent: Stephen Donovan

20080260804 - Medical devices having antimicrobial coatings thereon: The present invention provides a medical device, preferably a contact lens, which comprises an antimicrobial coating including at least one layer of polyquat of formula (I) or (II). The antimicrobial coating on the medical device of the invention has a high antimicrobial efficacy against microorganisms including Gram-positive and Gram-negative bacterial,... Agent: Ciba Vision Corporation Patent Department

20080260805 - Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to... Agent: Hoffmann & Baron, LLP

20080260808 - Device for smoothing wrinkles on human skin: Device for smoothing wrinkles on human skin and for enabling skin sections between successive wrinkles to achieve prolonged contact with cosmetic and/or pharmaceutical substances carried by said device.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260806 - Personal hygiene compositions and methods: A personal hygiene composition, which may be coated on a towelette, comprises an astringent, a humectant, and a botanical extract. In some embodiments, the botanical extract can be selected from the group consisting of Hydrastis Canadensis, Tabebuia Impetiginosa, Hymenaea Courbaril, Ptychopetalum Olacoides, Juniperus Brasiliensis, Hamamelis Virginiana, and mixtures thereof. The... Agent: Harness, Dickey & Pierce, P.L.C

20080260809 - Polyethylene oxide-based films and drug delivery systems made therefrom: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component,... Agent: Hoffmann & Baron, LLP

20080260807 - Water-soluble films comprising nicotine: A water-soluble film comprising nicotine, wherein said nicotine may be any pharmacologically effective form of nicotine present at one or more locations of the film defined by the application of a nicotine-containing fluid to at least one surface of a preformed water-soluble film.... Agent: Mcdermott Will & Emery LLP

20080260810 - Hemostat: The present invention is directed towards a hemostat comprising an absorbable foam, an absorbable woven or knitted fabric, thrombin and/or fibrinogen.... Agent: Philip S. Johnson Johnson & Johnson

20080260811 - Transdermal delivery systems: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form... Agent: Thomas P. Mccracken Durect Corporation

20080260812 - Therapeutic medicine containing monoclonal antibody against folate receptor beta (fr-beta): An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260813 - Pharmaceutical composition of topiramate: The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical... Agent: Philip S. Johnson Johnson & Johnson

20080260814 - Injection moulding process for neutral and acid-group-containing (meth)acrylate copolymers: Processes for producing moldings by injection moulding, include melting a mixture made from a (meth)acrylate copolymer and a release agent, devolatilizing the mixture, injecting the molten and devolatilized mixture into a mold cavity of an injection mold, cooling the molten mixture, and removing the resultant molding from the mold.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080260815 - Multiparticulates: Extrusion of a mix containing a pharmaceutically active agent can be achieved using a plasticising excipient in an amount sufficient to act as plasticiser and also act as lubricant, thereby avoiding the need for inclusion of a lubricant. The invention provides multiparticulates with controlled release properties, substantially free of lubricant.... Agent: Duane Morris LLP - Ny Patent Department

20080260816 - Particulate lipid pharmaceutical composition: A particulate lipid pharmaceutical composition comprises a particulate solid non-lipid carrier and an oil-in-water emulsion on the carrier. The emulsion comprises a dissolved or dispersed pharmacologically active agent. The oil-in-water emulsion is released from the carrier on contact with an aqueous media to form an oil-in-water emulsion in the media.... Agent: Nixon & Vanderhye, PC

20080260817 - Compositions for the treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist: The present invention provides a therapeutic composition comprising a COX-2 selective inhibitor or a prodrug thereof and an LTB4 receptor antagonist. A method is provided for the use of such composition in the treatment, prevention, or inhibition of inflammation, an inflammation-related disorder, pain, or a pain-related disorder.... Agent: Pharmacia Corporation Global Patent Department

20080260818 - Controlled absorption of statins in the intestine: The present invention provides a controlled absorption formulation in which modified release of active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient into the body of the subject than can be achieved from the currently used... Agent: Winston & Strawn LLP Patent Department

20080260819 - Sustained release compositions of drugs: A sustained release pharmaceutical composition has been developed. The composition resists dose dumping when broken, crushed or chewed, which enhances the safety of the dosage form should it be accidentally or intentionally physically compromised. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080260821 - Berry preparations and extracts: A method for deriving compositions having antioxidant and anti-inflammatory activity from berries is provided. The method results in a berry extract compositions having stable anthocyanin content. In one aspect, the method comprises exposing a berry to a solvent composition having a pH of from about 1 to about 4.5, and... Agent: King & Schickli, PLLC

20080260820 - Oral dosage formulations of protease-resistant polypeptides: Oral dosage formulations of the protease-resistant therapeutic polypeptides are provided. The dosage formulations for administration per dosage per day or per week are higher than the subcutaneous dosage. Included among the oral dosage formulations are tablets and capsules, including enteric-coated forms. Methods for treatment or prevention of diseases or conditions... Agent: Bell, Boyd & Lloyd LLP

20080260822 - Synthesis of human secretory iga and igm and the formation of a medicament therefrom: A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080260823 - Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea: The invention provides an orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate for treating sialorrhea, as well as a kit comprising the orally disintegrating tablet, prescribing information, and a container. The invention also provides a method of treating sialorrhea in a patient comprising administering the orally disintegrating tablet... Agent: Leydig Voit & Mayer, Ltd

20080260824 - Bioadhesive rate-controlled oral dosage formulations: The present invention relates to a bioadhesive drug delivery system (BIOadhesive Rate controlled Oral Dosage (BIOROD) formulation) in which a drug containing core either alone or coated with a rate controlling membrane system is enveloped on its circumference by a bioadhesive coating, thereby yielding a monolithic system that allows for... Agent: Ropes & Gray LLP

20080260825 - Methods and compositions for reduction of side effects of therapeutic treatments: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a... Agent: Wilson Sonsini Goodrich & Rosati

20080260826 - Pharmaceutical composition and process: The present invention relates to a method of forming granules of (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl isobutyrate; hydrochloride salt (I), comprising mixing I, with a granulating amount of a granulating liquid, and a polyethylene glycol (PEG)/polypropylene glycol (PPG) block copolymer as a binder and solubility enhancer to form wet granules which are then dried... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080260827 - Risedronate compositions and their methods of use: A method comprising orally administering to a human or other mammal a pharmaceutical composition comprising from about 65% to about 110% of the cumulative effective dose of risedronate or a pharmaceutically acceptable acid, salt, ester, solvate, or polymorph thereof according to a continuous dosing schedule of one, two, or three... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080260828 - Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it: This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30,000.... Agent: Buchanan, Ingersoll & Rooney PC

20080260829 - Bmp gene and fusion protein: This invention relates to BMP fusion genes, BMP fusion proteins. The invention further relates to methods for treatment using BMP fusion genes and BMP fusion proteins. Additionally, the invention relates to BMP fusion gene and BMP fusion protein pharmaceutical compositions.... Agent: Darby & Darby P.C.

20080260831 - Extracellular matrix-derived gels and related methods: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which... Agent: Jesse A. Hirshman, Esq.

20080260830 - Growth factor mutants with improved biological activitiy: The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080260833 - Drug delivery vehicle containing vesicles in a hydrogel base: A drug delivery vehicle having active agent loaded vesicles in a hydrogel matrix; desirably either or both of the vesicles and matrix are made of at least one stimulus responsive polymer so that active agent is released in response to contact with a stimulus.... Agent: Law Office Of Collen A. Beard, LLC

20080260832 - Sustained release intraocular implants and methods for preventing retinal dysfunction: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable... Agent: Allergan, Inc.

20080260834 - Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders: Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080260835 - Pharmaceutical compositions for poorly soluble drugs: The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may... Agent: Birch Stewart Kolasch & Birch

20080260836 - Films comprising a plurality of polymers: Films are disclosed that comprise a first polymer and a second polymer having a solubility temperature lower than that of the first polymer; wherein the breaking strength of the film is greater than about 750 psi (5,171 kPa). Also disclosed are compositions comprising such films that are useful as oral... Agent: Colgate-palmolive Company

20080260837 - Physically stable aqueous suspensions of active pharmaceuticals: The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides an aqueous pharmaceutical suspension composition comprising an active pharmaceutical component which is sparingly soluble to insoluble in water; a water soluble, low viscosity grade cellulose... Agent: Roberts & Roberts, LLP Attorneys At Law

20080260838 - Glucagon-like peptide 1 (glp-1) pharmaceutical formulations: A composition is disclosed comprising glucagon-like peptide 1 (GLP-1) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080260841 - Micronized wood preservative formulations: The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080260839 - Pulmonary formulation: The use of microparticles of silicon and particularly resorbable and/or photoluminescent silicon in the preparation of a medicament for nasal or pulmonary delivery. Aerosol formulations and their preparation are also described and claimed. These formulations may be used for example as carriers for pharmaceutical compounds as well as having diagnostic... Agent: Nixon & Vanderhye, PC

20080260840 - Suspension formulations of insulinotropic peptides and uses thereof: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic... Agent: Intarcia Therapeutics, Inc. Attn: Barbara G. Mcclung

20080260842 - Permeation enhancing compositions for anticholinergic agents: A transdermal or topical skin-friendly composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.... Agent: Winston & Strawn LLP Patent Department

20080260843 - transpulmonary composition: It is an object of the present invention to provide a transpulmonary preparation wherein physiologically active ingredient can be stably retained and which has high absorption efficacy and gives low damage to tissue. The present invention provides a transpulmonary preparation which comprises protein nanoparticles containing an active ingredient and having... Agent: Sughrue Mion, PLLC

20080260844 - Solid, oral, microparticulate dosage form which has been designed to prevent misuse: The invention relates to the field of solid, oral, microparticulate dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient contained therein. The aim of the invention is to prevent the improper use of solid oral medicaments for any use other than the therapeutic use(s) officially... Agent: Patton Boggs LLP

20080260845 - Multiple active drug resin conjugate: A combination pharmaceutical preparation including two different active drugs of the same ionic charge conjugated with a single resin particle, without one significantly displacing the other, and without retarding the initial availability of either active. Also, methods for the manufacture of a multiple active drug-resin conjugate, and for the in... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080260846 - Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof: The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically... Agent: Stetina Brunda Garred & Brucker

20080260849 - Composition for transmucosal absorption: It is an object of the present invention to provide a composition for transmucosal absorption which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high transmucosal absorbability. The present invention provides a composition for transmucosal absorption which comprises protein nanoparticles containing an active... Agent: Sughrue Mion, PLLC

20080260848 - Compositions that enable rapid-acting and highly absorptive intranasal administration: Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs.... Agent: Wilson Sonsini Goodrich & Rosati

20080260847 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080260850 - Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative: Delivery system for bioactive agents on the basis of a polymeric drug carrier formed from compositions comprising an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block having a terminal hydroxyl group substituted with a tocopherol or cholesterol group, and a polylactic acide derivative wherein one end of... Agent: LexyoumeIPGroup, LLC

20080260851 - Polymeric nanoparticles and nanogels for extraction and release of compounds: The invention relates to polymeric nanoparticles and nanogels, which can contain, deliver, and/or release one or more active agents, such as biologically active molecules or fragrance molecules, and methods of preparing the polymeric nanoparticles and nanogels. The nanoparticles are crosslinked utilizing radiation (g-radiation) as the catalyst for free radical polymerization... Agent: Schwegman, Lundberg & Woessner, P.A.

20080260852 - Supercritical fluid extraction produced by in-line homogenization: A method for producing micro and/or nanoparticles by contacting an emulsion with a supercritical fluid. The method can be used to produce an aqueous suspension of particles that include a drug encapsulated in a polymer. The drug and polymer are dissolved in an organic solvent to form an organic solution.... Agent: Rankin, Hill & Clark LLP

20080260853 - Extracellular matrix as surgical adjunct in a lumpectomy procedure: The invention an article or composition of mammalian extracellular matrix (ECM) for placement in a lumpectomy space of a breast after tumor removal. The extracellular matrix article or composition can regenerate lost breast tissue, reduce the formation of scar tissue at the site of excision, and reduce a likelihood of... Agent: Leigh Hunt Firestone

20080260854 - Sirna molecules for the treatment of blood vessels: The present invention relates to a nucleic acid molecule, a genetic construct, siRNA molecules and a composition which comprises the nucleic acid molecule and/or the genetic construct and/or the siRNA molecules and can be used for inhibition of the expression of endothelial adhesion molecules. The invention also relates to a... Agent: Klarquist Sparkman, LLP

20080260855 - Processed water and therapeutic uses thereof: A physiologically ingestible composition of matter obtained by preparing oxygenated water with a stable negative oxidation reduction potential (ORP), and the uses thereof, are provided. The obtaining method includes preconditioning water received from a water source for electrolysis, performing electrolysis on the preconditioned water, outputting alkaline water and/or acidic water... Agent: Rene A. Vazquez Williams Mullen

20080260857 - Substance and method for treating neoplasms: The invention relates to substance and method for treating neoplasms in mammals. A substance for treating neoplasm comprises water comprising from 99.76 to 99.99 molecular % of light isotopologue 1H216O and up to 100% of residual isotopologues. A method for treating neoplasm comprises a step of administering to a mammal... Agent: Notaro And Michalos

20080260856 - Topical composition containing sacred water: Topical compositions having as at least one part of their composition sacred and/or holy water. These compositions are useful for imparting a spiritual sense of well-being.... Agent: The Halvorson Law Firm

20080260858 - Universal procoagulant: A thromboplastin reagent comprises: (i) activated sTF, (ii) a metal-chelating lipid, (iii) a metal ion, and (iv) a phospholipid. Activated sTF preferably includes the extracellular domain of TF and an oligohistidine moiety having at least 2 histidine residues, more preferably 2-10 histidine residues. Preferably, the histidine residues are consecutive. Attaching... Agent: Evan Law Group LLC

20080260859 - Composition containing omega-3 fatty acids and omega-6 fatty acids: A composition comprises at least an omega-3 fatty acid, at least an omega-6 fatty acid, and zinc. The composition is advantageously administered to a subject suffering from a condition of dry eye. In certain embodiment, the amount of omega-3 fatty acid is much higher than that of the omega-6 fatty... Agent: Bausch & Lomb Incorporated

20080260860 - Method for the acaricidal finishing of textile materials: The use is described of zinc pyrithione for finishing woven and non-woven textiles to render them resistant against colonization by house dust mites. Zinc pyrithione is used alone or in combination with other actives with or without other textile chemicals. The formulations comprising zinc pyrithione are applied to the textiles... Agent: Nixon Peabody, LLP

20080260861 - Modulating lymphatic function: Methods and compositions for modulating lymphatic function, e.g., by altering NO levels, are disclosed.... Agent: Fish & Richardson PC

20080260862 - Composition for treatment and prevention of bone loss: The composition set forth provides for the prevention and treatment of bone loss and osteoporosis. The formulation combines Vitamin D; Calcium Citrate Malate; Potassium Citrate; Magnesium; Boron and Vitamin K. Each component has an effect on its own combined with a synergistic effect with the other components.... Agent: Hoffman, Wasson & Gitler, P.C.

20080260863 - Compositions for mucociliary clearance and methods for administering same: Sterile, preservative-free premeasured hypertonic saline solutions may be administered to individuals afflicted with cystic fibrosis to increase mucolciliary clearance and to improve lung function. In particular, a 7% hypertonic saline solution may be administered at least 2 times a day, using a jet and/or vibrating-mesh nebulizer to an individual afflicted... Agent: Mcguirewoods, LLP

20080260864 - Topical compositions for the treatment of depilation-induced irritation or prevention thereof: The present invention relates to topical compositions comprising as active ingredients Aluminium Chloride and Sulfur for treatment of skin irritation induced by depilation. Said compositions have pharmaceutical and/or cosmetic and/or quasi cosmetic properties. The present invention also involves methods of making and methods of using such compositions. Furthermore, the present... Agent: Moore & Van Allen PLLC

20080260865 - Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite: Methods for treating bacterial respiratory tract infections in an individual comprise administering a therapeutic amount of nitrite composition having a pH of less than 7, and in specific embodiments, a pH of about 5.5-6.5, to the individual. The individual may be a pulmonary disease diagnosed individual and/or the infection may... Agent: Seed Intellectual Property Law Group PLLC

20080260866 - Method for decreasing inflammation and stress in a mammal: The present invention is directed to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080260867 - Hair growth stimulants and the manufacturing method thereof: A hair growth stimulant having excellent hair growth stimulation and hair growth effects without any side effects, which contains a carbonized pine cone. The inventive hair growth stimulant has an excellent hair growth stimulation effect without causing any side effects or toxicity to the human body, while it can stimulate... Agent: Iphorgan, Ltd.

20080260868 - Folate based composition for neurological and cognitive applications: New formulations for the prevention and treatment of neurological diseases and cognitive deficiencies, particularly Alzheimer's Disease comprise folate in combination with compounds chosen to address some or all of the pathways which can result in neurological deficiencies and diseases, namely inflammation, oxidative stress, glycation/dysinsulinemia, platelet function, homocysteine levels and acetylcholinesterase... Agent: Venable LLP

20080260869 - Magnolia extract containing compositions: Disclosed is a composition comprising at least two of the following ingredients: Magnolia extract, honokiol, humulus lupulus extract, hesperidin methyl chalcone, gotu kola, dipeptide valyl-tryptophane, palmitoyl tetrapeptide-3, corylus avellana bud extract, centella asiatica extract, cucumis sativa extract, morus alba extract, hibiscus sabdariffa flower extract, vitis vinifera extract, ascorbyl glucoside, citrus... Agent: Fulbright & Jaworski L.L.P.

20080260870 - Compositions for protecting liver, or for preventing or treating liver fibrosis or cirrhosis: Disclosed is a composition for hepatoprotection, or for prevention or treatment of liver fibrosis or cirrhosis, which comprises as an active ingredient a water extract of a mixture of Trionycis Carapax, Raphani Semen, Artemisia capillaris Herba, Atractylodis Macrocephalae Rhizoma, Poria cocos, Alismatis Rhizoma, Atractylodis Rhizoma, Salvia Miltiorrhizae Radix, Polyporus, Amomi... Agent: Lee, Hong, Degerman, Kang & Schmadeka

20080260872 - Gro-protect solutions: Gro-Protect Solutions is applied to the natural hair (wherever gluing products will be applied) It is recommended that the natural hair is completely dry before applying Gro-Protect Solutions. Once Gro-Protect Solutions is applied to the natural hair it needs to be dried underneath a heated dryer (it can also dry... Agent: Calvin Lee Garris

20080260871 - Method and composition for infusing herbal extracts and pharmaceuticals through the skin: A topical mixture, that when massaged onto the skin, enables infusion of drugs or herbal compounds into deeper tissues, and a method of enhancing the penetration and concentration of drugs and herbs into tissues, especially as relates to treatment of pain.... Agent: Snell & Wilmer L.L.P. (main)

20080260873 - Agent for prevention or improvement of neuropathy comprising pre-germinated brown rice lipid fraction as an effective ingredient: t

20080260875 - Novel skin care compositions and methods: Skin care compositions and methods are provided comprising a highly hydrophobic substance, an alkaryl polyfluorocarbon, particularly a substituted phenyl-polyfluoroacylamino propanamide, an alkanol and refined oils and the oil triglyceride fractions in sufficient amount to provide substantial homogeneity. When employed for hirsutism, optionally antioxidants and moisturizer are added. For use against... Agent: Peters Verny , L.L.P.

20080260874 - Peripheral blood flow-improving composition: The present invention provides a composition that can effectively improve peripheral blood flow to thereby ameliorate cold sensation, numbness, pains and other skin symptoms, as well as frostbites, chilblains and chaps and other skin disorders associated with disturbed peripheral blood flow. This composition has no side effects. Specifically, the peripheral... Agent: Drinker Biddle & Reath (dc)

20080260876 - Garlic extract compositions, uses and preparations thereof: The present invention relates to compositions comprising a garlic extract and chitosan or a salt thereof. These compositions present an enhanced antifungal activity, or activity for controlling powdery mildew disease, in various types of plants, vegetables, fruits or flowers, particularly when compared to garlic extract alone or to chitosan or... Agent: Ogilvy Renault LLP

20080260877 - Plant extracts and compositions for reducing blood lipid levels: An extract of a plant of the genus Gynostemma is described. The extract is obtainable by a process wherein an aqueous extract is further extracted with n-butanol. The extract has a high level of actives, such as saponins, and/or a low level of impurities. The extract is particularly suitable for... Agent: Unilever Patent Group

20080260878 - Composition for prevention or alleviation of pigmentation: A composition for the prevention or alleviation of pigmentation which can produce the higher effect of preventing or alleviating pigmentation. The composition for the prevention or alleviation of pigmentation comprises a combination of (A) at least one member selected from the group consisting of adenosine 5′-monophosphate and salts thereof with... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080260879 - Use of paeonia and extracts thereof with growth promoting activity in veterinary medicine and zootechnics: The present invention relates to the use of extracts of plants or roots of the Paeonia genus, in particular Paeonia lactiflora, for the preparation of growth promoters for use in livestock.... Agent: Young & Thompson

20080260880 - Oral compositions for the prevention of uv damages: The invention relates to oral compositions for the prevention of UV damages, in particular to oral compositions based on an olive extract obtained by extracting vegetation water from olive pressing with an organic solvent or by extracting olive cake with water and/or an organic solvent.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20080260881 - Blue-green algae composition: A broad spectrum functional food formulation based on blue-green algae and concentrated extracts of blue-green algae provides numerous health benefits when orally administered in therapeutically effective amounts. Whole aphanizomenon flos-aqua is combined with concentrates of phycocyanin and phenylethylamine to provide a life-enhancing dietary supplement which can stimulate stem cell production,... Agent: Lawrence J. Shurupoff

20080253961 - Formulation of active agent loaded activated plga nanoparticles for targeted cancer nano-therapeutics: The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and... Agent: Chalker Flores, LLP

20080253960 - Lipoprotein-based nanoplatforms: The present invention provides a non-naturally occurring lipoprotein nanoplatform (“LBNP”) comprising at least one cell surface receptor ligand; at least one lipoprotein; and at least one diagnostic agent and/or at least one therapeutic agent. In embodiments of the present invention, the cell surface receptor ligand is not a low-density lipoprotein... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080253962 - Irta-4 antibodies and their uses: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-4 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions... Agent: Baker Botts L.L.P.

20080253964 - Methods and compositions for f-18 labeling of proteins, peptides and other molecules: The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not limited to aptamers, oligonucleotides and nucleic acids may... Agent: Immunomedics, Inc.

20080253963 - Tumor markers in ovarian cancer: The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating... Agent: National Institute Of Health C/o Ballard Spahr Andrews & Ingersoll, LLP

20080253965 - Small-molecule hsp90 inhibitors: with a 2′,4′,5′-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4′ and 5′ positions on the aryl group, wherein X1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido,... Agent: Marina Larson & Associates LLC Re: Msk

20080253966 - Diagnostic, prognostic, and therapeutic factor smac/diablo in human cancer: The present invention provides, for the first time, the finding that Smac/DIABLO is underexpressed in cancers such as renal cell carcinoma. In particular, the present invention provides methods of diagnosing and providing a prognosis for cancers that underexpress Smac/DIABLO, as well as methods of drug discovery to identify therapeutics useful... Agent: Townsend And Townsend And Crew, LLP

20080253967 - Halo-stilbene derivatives and their use for binding and imaging of amyloid plaques: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a... Agent: Woodcock Washburn LLP

20080253969 - Multi-functional polyglutamate drug carriers: Various biodegradable polyglutamate polymer conjugates that can include recurring units of the general formulae (I) and (II) are described herein. Such polymer conjugates are useful for variety of drug, targeting, stabilizing and/or imaging agent delivery applications.... Agent: Knobbe Martens Olson & Bear LLP

20080253968 - In vivo examination method: It is possible to perform quantitative examination of biological tissue even with a solution composed of a near-infrared fluorescent dye and a polypeptide. An image acquired before administering a reagent is subtracted from an image acquired after administering the reagent to remove regions appearing in both images, such as autofluorescence,... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20080253970 - Stable pharmaceutical drug products: Various aspects of the present invention provide for methods of manufacturing a pharmaceutical drug product, which include storing a container at a temperature greater than ambient conditions for at least about seven days and conducting release testing on the container after storing. Products manufactured by this method have a more... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080253972 - Aqueous/alcoholic deodorant composition comprising a water-soluble zinc salt and salicylic acid: The present disclosure relates to a deodorant composition comprising, in a cosmetically acceptable medium: a) at least one water-soluble zinc salt; b) salicylic acid; c) at least one C1-C5 monoalcohol; and d) at least 2% by weight of water, relative to the total weight of the composition. Another aspect of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080253973 - Sensation modifying topical composition foam: This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical, therapeutic and cosmetic compositions, comprising an active agent, having a sensation or sensation modifying affect on a body surface,... Agent: Wilmerhale/boston

20080253974 - N-phenyl-n-pyridinyl-benzamides and benzenesulfonamides having cooling properties: Used as cooling agents are the compounds of formula (I), wherein Y is carbonyl (C(═O)) or sulfonyl (SO2—); and X is O CH3, CN, C(═O)NHR, C(═O)OR, or halogen; and R is hydrogen or C1-C4 alkyl.... Agent: Curatolo Sidoti Co., Lpa

20080253975 - Composition for dyeing dental plaque for evaluating dental caries activity: An objective of the present invention is to provide a composition for dyeing dental plaque for evaluation of dental caries activity that is capable of simultaneously dyeing dental plaque and evaluating dental caries activity, and which can evaluate thick dental plaque more accurately than the conventional technique. The composition for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080253976 - Personal care compositions comprising an antimicrobial blend of essential oils or constituents thereof: Disclosed are personal care compositions, including compositions for oral, throat and skin care comprising a blend of naturally occurring flavor or perfume ingredients or essential oils containing such ingredients, wherein the blend provides excellent antimicrobial activity and comprises at least two components, a first acyclic component selected from citral, neral,... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080253978 - Derivatives of pyrrolyltriazine together with methods for obtaining them and their use as protecting agents uv radiation: The present invention relates to new pyrrolyltriazine derivatives of general formula (I) together with method for obtaining them. The physico-chemical properties of said compounds allow them to be used as absorbents of UV radiation.... Agent: Berenbaum, Weinshienk & Eason, P.c

20080253977 - Novel plant gene and uses thereof: A novel gene isolated from Deschampsia antarctica coding for a lipase like protein is disclosed. A system for production of recombinant enzyme is also disclosed as well as uses for the enzyme.... Agent: Dodds & Associates

20080253979 - Method for the treatment of nail disease: A treatment for diseased nails comprises treating the diseased nail after thorough cleaning with a peroxide solution, and thereafter applying an iodine solution until the diseased nail has recovered.... Agent: Ursula B. Day Ursula B. Day, Esq.

20080253980 - Method of making up nails: The present invention is directed to a method of making up nails, the method involving: a) applying onto the nails a first composition containing: i) at least one color precursor, ii) at least one film former, iii) at least one volatile solvent, iv) optionally, at least one buffer, and v)... Agent: L'oreal Usa/ Patent Department

20080253981 - Stabilized body care products, household products, textiles and fabrics: Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain sterically hindered amine salt compounds. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products,... Agent: Joann Villamizar Ciba Corporation/patent Department

20080253982 - Ascorbic acid derivatives and skin-whitening cosmetics: s

20080253983 - Sos - daily control for shiny and oily skin, hair, bald scalp, and body:

20080253984 - Methods of inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis: A method for treating onychomycosis and skin conditions such as urushiol-induced allergic contact dermatitis comprises coating the affected nail or skin with a solution comprising an at least a primary diamine with modified diphenylmethane diisocyanates and a carrier solvent/reactant.... Agent: Myers Bigel Sibley & Sajovec

20080253985 - Compositions for lowering serum cholesterol and/or triglycerides: The invention provides methods and compositions for treating hyperlipidemia and disorders associated with hyperlipidemia in a mammal. Compositions useful in the practice of the invention include a microsomal triglyceride transport protein inhibitor (“MTPI”) and at least two other cholesterol lowering drugs selected from the group consisting of a cholesterol absorption... Agent: Goodwin Procter LLP Patent Administrator

20080253986 - Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers: Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.... Agent: Buchanan, Ingersoll & Rooney PC

20080253987 - Polymeric tissue sealant: The precursors are selected based on the desired properties of the biomaterial. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to reduce, inhibit, or contain loss of a biological fluid or gas in a patient.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080253991 - Anti-t cell and autoantigen treatment of autoimmune disease: The invention is directed to a new method for the treatment of new onset Type I diabetes in mammals or for the treatment of pre-Type I diabetic mammals where the method comprises administering (a) anti-T cell therapy to the mammal and administering (b) an autoantigen and optional mucosal antigen composition,... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20080253993 - Immunogenic egfr peptides comprising foreign t cell stimulating epitope: Disclosed is a method for inducing an immune response against autologous Epidermal Growth Factor Receptor (EGFR) in humans. The method comprises effecting uptake by antigen presenting cells of epitopes (preferably all) from the extracellular portion of human EGFR and of at least one non-human T helper epitope (TH epitope) so... Agent: Birch Stewart Kolasch & Birch

20080253994 - Methods and compositions for contributing to the treatment of cancers: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080253992 - Methods for the purification of polypeptide conjugates: The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an... Agent: Morgan, Lewis & Bockius LLP (sf)

20080253995 - Modified fluorinated nucleoside analogues: The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.... Agent: Duane Morris LLPIPDepartment

20080253989 - Neuron regeneration: The invention provides a gene silencing molecule, which is adapted to down-regulate expression of a gene encoding a peptide involved with the Rho-A inhibitory pathway. The gene silencing molecule is used to promote neuron survival and axon regeneration in the central nervous system (CNS). The invention also provides compositions and... Agent: Michael Best & Friedrich LLP

20080253988 - Pyrrolo [1,2-d] [1,2-4] triazine as inhibitors of c-jun n terminal kinases (jnk) and p-38 kinases: A compound of formula (I): wherein the substituents are as defined in the specification as inhibitor of C-Jun N terminal Kinases (JNK) and P-38 Kinases.... Agent: Novartis Corporate Intellectual Property

20080253990 - Self-containing lactobacillus strain: The invention relates to a recombinant Lactobacillus strain, with limited growth and viability in the environment. More particularly, it relates to a recombinant Lactobacillus that can only survive in a medium where thymidine is present. By this strict dependency upon thymidine, thymidineless death is rapidly induced in this recombinant strain.... Agent: Trask Britt

20080253996 - Use of sdf-1 for the treatment and/or prevention of neurological diseases: The invention relates to the use of SDF-1, or of an agonist of SDF-1 activity, for the treatment and/or prevention of a neurological disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080253997 - Compositions and methods for protecting cells from toxic exposures: The present invention provides compositions and methods for protecting cells and tissues from damage associated with therapeutic treatments of cancers and other diseases and conditions where reactive oxygen species are produced. The present invention also provides compositions useful as research reagents.... Agent: Casimir Jones, S.c.

20080253998 - Treatment of cancer using tlr3 agonists: The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080254008 - Lentiviral vectors and their use: The present invention relates to lentiviral vectors for gene therapy, cancer treatment, producing recombinant proteins, such as antibodies and vaccines, and other therapeutic purposes. Novel lentiviral vectors are disclosed, e.g., comprising helper sequences in opposite orientations and/or minimally functional LTR sequences, which can be used to prepare high efficiency transduction... Agent: Jones Day

20080253999 - Methods for differentiating stem cells and uses thereof in the treatment of dental conditions: e

20080254000 - Methods of improving the yield and/or quality of aquatic or marine animals: Methods of treating aquatic or marine animal water bodies including contacting the water body with one or more sulfur oxidizing bacteria such as those selected from the genus Paracoccus in an amount sufficient to control, reduce, or eliminate the H2S in the water body is disclosed. One or more sulfur... Agent: Novozymes North America, Inc.

20080254009 - Method of treating gastrointestinal diseases associated with species of genus clostridium: The invention includes a method of treating gastrointestinal diseases associated with species of genus Clostridium such as clostridium deficit in human patients with gastrointestinal disorders having an etiological component such as a microbial agent producing a toxin where treated with an antimicrobial composition an amount effective to inhibit or eliminate... Agent: Blank Rome LLP

20080254010 - Controlling clostridium difficile-associated disease in the gastrointestinal tract: This document provide materials and methods for treating patients infected with a spore-forming bacteria and materials and methods for preventing development of Clostridium difficile-associated disease.... Agent: Fish & Richardson P.C.

20080254012 - Nutritional formulation for promoting catch-up growth: This invention relates to a nutritional formulation comprising an n3 long-chain polyunsaturated fatty acid (LC-PUFA), a prebiotic fibre and a probiotic bacterial strain which ingredients act together in a synergistic fashion to promote catch-up growth in young mammals whose growth has been retarded because the young mammal has been subjected... Agent: Bell, Boyd & Lloyd LLP

20080254011 - Use of selected lactic acid bacteria for reducing atherosclerosis: Strains of lactic acid bacteria selected for their capability of increasing the BSH-activity and consequently lowering serum LDL-cholesterol, and simultaneously decreasing the pro-inflammatory cytokine TNF-α levels, for prophylaxis and/or treatment of atherosclerosis and other cardiovascular diseases, a method of selecting such strains, and products containing such strains.... Agent: Lynn E Barber

20080254013 - Method of reducing nematode damage: A method of reducing damage to plant propagation material and plant organs which grow at a later time by a representative of the class Nematode, which method comprises (I) treating the propagation material with (A) a chelating agent, and optionally (B) a macrocyclic lactone compound or another pesticide, before the... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080254014 - Use of recombinant yeast strain producing an anti-inflammatory compound to treat colitis: An administration strategy is disclosed for the delivery at the intestinal mucosa of anti-inflammatory compounds, preferably acid-sensitive anti-inflammatory agents, such as IL10 and/or a soluble TNF receptor and/or trefoil factor via the oral route. In particular, inoculation with a suspension of live recombinant yeast cells, preferably Saccharomyces cells, which have... Agent: Knobbe Martens Olson & Bear LLP

20080254002 - Bone marrow derived oct3/4+ stem cells: The invention provides bone-marrow derived stem cells, e.g., cardiomyocyte precursor cells, differentiated cardiomyocytes generated from the precursor cells, and a method for treating cardiac dysfunction in a subject by administering such cells.... Agent: Hoffmann&baron

20080254003 - Differentiation of human embryonic stem cells and cardiomyocytes and cardiomyocyte progenitors derived therefrom: The present invention provides a method to improve current culturing methods for the differentiation of cardiomyocytes from hES cells. The method includes culturing the hES cells in the presence of ascorbic acid or a derivative thereof. Preferably the culturing is conducted in serum free conditions. The invention also includes isolated... Agent: Scully Scott Murphy & Presser, PC

20080254004 - Homogeneous neural precursor cells: This invention provides pure populations of neural precursor cells, capable of differentiation into neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural precursor population. The precursors can... Agent: Woodcock Washburn LLP

20080254007 - Human mesenchymal progenitor cell: The present invention provides isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), which simultaneously express a plurality of genes that are markers for multiple cell lineages, wherein the multiple cell lineages comprise at least four different mesenchymal cell lineages (e.g., adipocyte, osteoblast, fibroblast, and muscle cell) and wherein each of the... Agent: Glenn P. Ladwig Saliwanchik, Lloyd & Saliwanchik

20080254001 - Novel bone mineralization protein expression systems, and methods of studying their intracellular signaling pathways: The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors.... Agent: Medtronic Spinal And Biologics Attn: Noreen Johnson -IPLegal Department

20080254005 - Stem cell therapy for the treatment of autism and other disorders: Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of inducing angiogenesis and immune modulation either in sequence or parallel in order to substantially ameliorate or reverse the progression of autism. The... Agent: Baumgartner Patent Law

20080254006 - Treatment of alopecia by micropore delivery of stem cells: A method of restoring hair to skin that has suffered hair loss includes optically ablating an array of spaced-apart microchannels or voids into the skin and transplanting into the voids stem cells, a scaffold and a differentiation factor for causing the stem cells to differentiate into hair follicles.... Agent: Reliant / Fenwick C/o Fenwick & West, LLP

20080254016 - Composition for increasing anti-oxidation activity in blood: m

20080254015 - Gel composition of citrus complex carbohydrates cross-linked with cellulose derivate: A gel for application to a wound, comprising a mixture of citrus complex carbohydrates, a cellulose derivative, a polyol component and water, wherein said citrus complex carbohydrates are cross-linked to said cellulose derivative by an ionic cross-linking agent.... Agent: Mchale & Slavin, P.A.

20080254017 - Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids: The invention as disclosed herein provides pharmaneutical compositions and methods for treating, ameliorating, or preventing the symptoms of fatty acids imbalance and cell membrane dysfunction. The pharmaneutical compositions of the invention contain in an effective amount a first and a second composition, the first composition comprises an effective amount of... Agent: Law Offices Of Khalilian Sira, LLC

20080254018 - Immobilized angiogenin mixtures and uses thereof: Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by covalent immobilization on a naturally occurring substrate, such as a polysaccharide substrate, are disclosed. In particular, the polysaccharide substrate includes galactose-rich polysaccharide.... Agent: Knobbe Martens Olson & Bear LLP

20080254019 - Therapeutic agents and therapeutic methods for treating injured tissue: This invention provides therapeutic agents, transplants and therapeutic methods that can enhance the regeneration of injured tissue. This invention relates to agents, transplants and therapeutic methods for enhancing the migration and accumulation of mesenchymal stem cells in injured tissues and/or suppressing the diffusion of mesenchymal stem cells from injured tissues.... Agent: Birch Stewart Kolasch & Birch

20080253971 - Particles for inhalation having sustained release properties: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of... Agent: Elmore Patent Law Group, PC

20080254020 - Therapeutic peptides: The invention relates to compounds that exhibit improved bioefficacy in multidose administration. More specifically, the invention relates to polypeptides or peptides modified to include an antibody Fc region and one or more water soluble polymers.... Agent: Marshall, Gerstein & Borun LLP

20080254021 - Tie1-binding ligands: Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that inhibit endothelial cell activity.... Agent: Lowrie, Lando & Anastasi, LLP

20080254022 - Method of treating airway diseases with beta-adrenergic inverse agonists: The use of β-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a β-adrenergic inverse agonist to the subject to treat... Agent: Catalyst Law Group, Apc

20080254026 - Antagonist anti-cd40 monoclonal antibodies and methods for their use: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof... Agent: Alston & Bird LLP

20080254024 - Anti-ephb2 antibodies and methods using same: The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.... Agent: Genentech, Inc.

20080254028 - Caspase-8 binding protein, its preparation and use: The present invention relates to a caspase-8 interacting polypeptide (Cari), methods for its preparation, and its use.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080254025 - Human il-1 epsilon dna and polypeptides: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in cellular and immune reactions, the use of such polypeptides in screening... Agent: Immunex Corporation

20080254027 - Optimized cd5 antibodies and methods of using the same: The present invention describes antibodies that target CD5, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20080254023 - Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor: The present invention relates to a method of treating disorders of the nervous system and more particularly disorders associated with a gliotic response and/or an inflammatory response within the central nervous system and to therapeutic agents useful for same. More particularly, the present invention involves a method of preventing or... Agent: Foley And Lardner LLP Suite 500

20080254029 - Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis: Disclosed are methods of treating allergic conjunctivitis and allergic rhinitis in a subject that involve topically administering to the subject a composition comprising a pharmaceutically effective amount of an H1 antagonist and an anti-TNFα compound.... Agent: Alcon

20080254030 - Use of baff to treat th2-mediated conditions: Compositions and methods for treating Th2-mediated disease are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080254032 - Antibodies to m-csf: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single... Agent: Ropes & Gray LLP

20080254031 - Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis: Genes and variant RNAs that are differentially expressed in human colon tumor tissues compared with normal colon tissue and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of colon cancer.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080254034 - Basb119 polypeptide and polynucleotide from moraxella catarrhalis: The invention provides BASB119 polypeptides and polynucleotides encoding BASB119 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.... Agent: Ratner & Prestia- Sb Division

20080254035 - Lipocalin protein: The invention is based on the discovery that the human protein referred to herein as INSP181 protein is a lipocalin.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080254033 - Pharmaceutical compositions containing antagonists to lrp4, lrp8 or megalin for treatment of diseases: The present invention provides LRP4, LRP8 and LRP2 (megalin) polypeptides; polynucleotides encoding such; modulators of LRP4, LRP8 and LRP2 activity; and pharmaceutical compositions for the treatment of diseases. Compositions of the invention contain a pharmaceutically acceptable carrier or excipient and at least one modulator that is capable of binding to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080254036 - Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor: The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.... Agent: Foley & Lardner LLP

20080254037 - Method of treating ischemia reperfusion injury by inhibing nkt cell activity: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).... Agent: Schwegman, Lundberg & Woessner, P.A.

20080254038 - Immunogen adherence inhibitor directed to lactobacillus organisms and method of making and using it: A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the fermentators. The inhibitor is... Agent: Westman Champlin & Kelly, P.A.

20080254040 - Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080254039 - Prevention of thrombus formation and/or stabilization: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and preventing the formation and/or the stabilization of three-dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080254041 - Method for selecting an immunotherapeutic preparation: The present invention relates to a method for selecting one or more immunotherapeutic preparation having improved properties as a vaccine against a target antigen, said method comprising raising antibodies against a group of candidate preparations and selecting one or more preparations which produces antibodies having higher affinity against the target... Agent: Novozymes North America, Inc.

20080254043 - Drug for treating ischemic disease: The present invention relates to a pharmaceutical composition which includes a tissue factor inhibitor, which is administered after the onset of a thromboembolic ischemic disease, particularly after thrombus or embolus formation; a secondary thrombus formation inhibitor which includes a tissue factor inhibitor, which is administered after primary thrombus formation; a... Agent: Foley And Lardner LLP Suite 500

20080254042 - Novel use of prrp and receptor thereof: The present invention relates to provision of a method of screening a medicament using a disease-associated gene product, an antibody to the disease-associated gene product, and an antisense DNA which suppresses expression of the disease-associated gene product. Specifically, the present invention provides a protein comprising the same or substantially the... Agent: Edwards Angell Palmer & Dodge LLP

20080254045 - Modulation of nkt cell activity with antigen-loaded cd1d molecules: The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080254044 - Multivariable antigens complexed with targeting humanized monoclonal antibody: The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.... Agent: Chalker Flores, LLP

20080254047 - Activation of human antigen-presenting cells through clec-6: The present invention includes compositions and methods for using novel anti-CLEC-6 antibodies and fragments thereof for modulating the activity of immune cells.... Agent: Chalker Flores, LLP

20080254049 - Composition for treatment of colds and associated symptoms: A homeopathically designed composition comprising zinc and dilute amounts of Allium cepa and Aconite napellus for the alleviation of symptoms of a cold is provided. The composition may further comprise Antimonium crudum, Bryonia alba and Gelsemium.... Agent: Iovate Health Science Research Inc.

20080254048 - He4 monoclonal antibodies and methods for their use: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to HE4. Monoclonal antibodies having the binding characteristics of an HE4 antibody... Agent: Alston & Bird LLP

20080254046 - Method for the delivery of exogenous antigens into the mhc class i presentation pathway of cells: The present invention relates to an in vitro method that allows for delivery of exogenous antigens into the MHC class I presentation pathway of antigen-presenting cells (APCs), comprising the following steps: (a) preparation of suitable APCs; (b) determination of suitable specific method parameters for APCs, comprising (1) bringing the cells... Agent: Saliwanchick, Lloyd & Saliwanchik A Professional Association

20080254050 - Antiangiogenic active immunotherapy: e

20080254051 - Use of native peptides and their optimized derivatives for vaccination: The present invention pertains to the field of vaccination, and more particularly to the fields of antitumor and antiviral vaccination. The invention relates to the use of a native peptide in a medicinal composition, for selecting and/or boosting part of a CTL immune response which has been initiated by an... Agent: Alston & Bird LLP

20080254052 - Molecular differences between species of the m. tuberculosis complex: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb... Agent: Bozicevic, Field & Francis LLP

20080254053 - Protocol for treatment of diabetes: A method and composition for reducing highly sensitive C-reactive protein is provided for the treatment of Type I and Type II diabetes which is achieved through the daily administration of a leukotriene inhibitor, an antihistamine and a corticosteroid. The composition may be administered singly or as a single medicament. Typically,... Agent: The Weintraub Group, P.L.C

20080254054 - Fungal material stabilisation: A composition and methods of production are described including fungal material, a solid substrate and a biopolymer composition. The composition is described as being stable when stored for at least 7 months and also reduces dust losses normally attributed to fungal compositions. Uses are described for the composition including pest... Agent: Knobbe Martens Olson & Bear LLP

20080254055 - Compositions for regulation of hair growth: Personal care composition comprising at least one hair growth regulating compound selected from the group consisting of glyceryl dilaurate, apigenin, tetrahydrocurcumin, oleanolic acid, azelaic acid, sulforaphane, canavanine, pyridoxal 5-phosphate, phytic acid, tannic acid, grape seed extract, NG-nitro-L-arginine-methyl ester, benzamidine, sodium butyrate, betulinic acid, polyornithine, polyarginine, fisetin, jasmonates, methyl-jasmonate, cis-jasmone, caffeic... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080254056 - Green alga extract with high astaxanthin content and method of producing the same: A green algal extract that contains astaxanthin at a concentration of 8 wt % or more can be obtained by cultivating an encysted green alga in a nutrient medium while supplying carbon dioxide and providing irradiation with light at a photosynthetically active photon flux input of 8000 μmol-photon/m3/s or more,... Agent: Mcleland Patent Law Office, P.l.l.c.

20080254057 - Combined meningococcal conjugates with common carrier protein: Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimises the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunising a patient against a disease caused by Neisseria meningitidis,... Agent: Novartis Vaccines And Diagnostics Inc.

20080254058 - Pharmaceutical composition comprising a bacterial cell displaying a heterologous proteinaceous compound: The present invention pertains to a composition for the manufacture of a medicament comprising living or dead bacteria with controlled amounts of surface-coupled proteins or proteinaceous compounds and a method for the preparation of the composition. The bacterium provides a multivalent heterologous protein display vehicle that may be used in... Agent: Darby & Darby P.C.

20080254059 - Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby: Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g., fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among... Agent: Merck And Co., Inc

20080254060 - Genetically engineered equine influenza virus and uses thereof: The present invention relates, in general, to attenuated equine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated equine influenza viruses having modifications to an equine NS1... Agent: Jones Day

20080254061 - Mycobacteria expressing hiv-1 and malaria antigens: Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are Mycobacterium smegmatis expressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in... Agent: Amster, Rothstein & Ebenstein LLP

20080254062 - Use of an avirulent bordetella mutant as a live vaccine vector: The present invention pertains to Bordetella bacteria having a double mutation, a first mutation in a gene of the Type III secretion system and a second mutation in a gene of the adenylate cyclase toxin (CyaA) locus of the bacteria so that the mutations result in no Type III secretion... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20080254063 - Vaccines and methods to treat canine influenza: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine... Agent: Pharmacia & Upjohn

20080254064 - Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response: The present invention provides compositions and methods for inducing maturation of immature dendritic cells (DC) and for priming those cells for inducing a type 1 immune response. The present invention also provides dendritic cell populations useful for activating and for preparing T cells polarized towards production of type 1 cytokines... Agent: Townsend And Townsend And Crew, LLP

20080254065 - Influenza virus vaccines: The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable... Agent: Novartis Vaccines And Diagnostics Inc.

20080254066 - Nanoemulsion vaccines: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and... Agent: Casimir Jones, S.c.

20080254067 - Process for the production of an influenza vaccine: The present invention relates to a commercial-scale process for the production of influenza virus or antigens for prophylactic, diagnostic, immunotherapeutic or therapeutic purposes. Particularly, the invention provides a Madin-Darby Canine Kidney (MDCK)-derived, cell line and a cell culture-based process for the production of an influenza vaccine and more particularly, a... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080254068 - Novel vaccine for veterinary and human medicine prophylaxis and therapy: e

20080254069 - Vaccines for immunization against helicobacter: The invention relates to the immunisation of pigs against Candidatus Helicobacter suis using antigens of species related to Candidatus Helicobacter suis.... Agent: Clark & Elbing LLP

20080254070 - Streptococcus pneumoniae proteins and nucleic acid molecules: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.... Agent: Hunton & Williams LLP Intellectual Property Department

20080254071 - Homeopathic composition for alleviating allergy symptoms: The present invention is directed towards a homeopathically designed composition comprising effective amounts of Thussilago petasites (butterbur) and dilute amounts of Ambrosia artemisiifolia for the alleviation of symptoms of an allergy. According to various aspects, the present invention may further comprise combinations of Allium cepa, Echineacea angustifolia, Euphrasia officinalis (eyebright),... Agent: Iovate Health Science Research Inc.

20080254072 - Method for inhibiting scavenger receptor-a and increasing immune response to antigens: Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class A macrophage scavenger receptor (SR-A) and optionally administering the desired antigen. Also provided is a method for enhancing an... Agent: Hodgson Russ LLP The Guaranty Building

20080254073 - Transdermal patch comprising paroxetine: Disclosed relates to a transdermal patch comprising paroxetine that is useful to reduce the side effects accompanied with the initial high drug concentration after oral administration of paroxetine and decrease the broad metabolism of the drug in the liver. Moreover, the transdermal patch comprising paroxetine of the present invention has... Agent: LexyoumeIPGroup, LLC

20080254078 - Chitosan-based particles: The present invention provides a new binary system of hydrophilic nanoparticles and microparticles, using chitosan and polyanionic polysaccharides carrying carboxymethyl groups, sulfate groups or carboxy plus sulfate groups.... Agent: Sturm & Fix LLP

20080254074 - Composition and method for regulating sebum flow: A skin care composition for regulating sebum flow from sebocytes is described. The composition comprises spheroids, and optionally, thickening agents and when a spheroid and sebum mixture is made upon application, the resulting mixture leaves a pleasant, silky and powdery sensation.... Agent: Unilever Patent Group

20080254076 - Composition based on silicone oil structured in rigid form, especially for cosmetic use: s

20080254077 - Core/shell particles based on silicone compounds: The present invention relates to particles of core/shell type suitable for the encapsulation of cosmetic and/or therapeutic lipophilic active agents. It also relates to a process for preparing said particles as well as cosmetic or therapeutic compositions comprising them.... Agent: Oliff & Berridge, PLC

20080254075 - Cosmetic preparation for coloring of eyelids and eyebrows: An aqueous cosmetic preparation for coloring of eyelids and eyebrows contains 3-35 wt. % of an aqueous plastic dispersion based on an acrylate polymer and having a 30-50% solids content, 1-20 wt. % of at least one alcohol being ethanol and/or propanol, 2-25 wt. % of at least one moisture-retention... Agent: Merchant & Gould P.C.

20080254079 - Novel compositions containing lysozyme and c-1/c-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology: A composition comprising a content of a lysozyme and a content of a C-1/C-4 polysaccharide is useful in oral care, cosmetology and dermatology, contraception, urology and gynecology. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other... Agent: Norris, Mclaughlin & Marcus, Pa

20080254081 - Moist wipe and method of making same: A moist wipe having a web of fibers stabilized as with a suitable binder, and the stabilized, dry web having an anionic surface charge not greater than about 1.2 meq/Kg. A cationic functional agent in an aqueous imbuement is added to the web which is partially adsorbed by the web... Agent: Patent Group Ga030-43 Georgia-pacific LLC

20080254080 - Novel uses of calcium hydroxide: A heating ventilation and air conditioning (“HVAC”) system having bacterial spore, viral, and fungal killing activity. The HVAC system components are at least partially coated with a biocidal composition having hydrated lime, soluble binder polymer mixture and humecatant are mixed in either an organic based- or water based-solvent system that... Agent: T. Ling Chwang Jackson Walker

20080254082 - Methods for crop protection: The invention relates to a method for crop protection comprising administering to one or both of the crop and its environment a composition comprising a carrier; and microcapsules having a core material comprising a pesticide encapsulated by a silica shell, wherein the silica shell constitutes up to 10% w/w out... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080254083 - Dual action organic formulation to control two stages of insect pests: The present invention discloses systems and methods for controlling arthropod populations. The systems include a polymeric substrate, a semiochemical that is reactive upon an adult-stage arthropod, and an insecticide that is toxic to an immature-stage arthropod. The semiochemical may be a sex pheromone that disrupts mating behavior of the adult-stage... Agent: Stetina Brunda Garred & Brucker

20080254084 - Antimicrobial preparations having a content of octenidine dihydrochloride encapsulated in liposomes: The invention relates to antimicrobial preparations which comprise octenidine dihydrochloride in liposomes. The invention additionally relates to a process for manufacturing the preparations and to the use of phospholipids for manufacturing antimicrobial preparations which comprise octenidine dihydrochloride. The preparations show a low cytoxicity.... Agent: Young & Thompson

20080254086 - Controlled release compositions: Controlled release compositions for controlling release of a GnRH molecule or a GnRH analog are provided. The compositions include a GnRH molecule or GnRH analog as an active agent, and a controlled release component for controlling release of the GnRH molecule or GnRH analog from the composition. The compositions provide... Agent: Durect Corporation Thomas P. Mccracken

20080254085 - Degradable polymers incorporating gamma-butyrolactone: Disclosed herein are implantable medical devices having controlled release biodegradable polymer coatings thereon wherein the polymer is formed from ring opening of γ-butyrolactone and at least one additional monomer selected from the group consisting of trimethylene carbonate, lactide, polyethylene glycol, glycolide, the monomers formed from ring opening of ε-caprolactone, 4-tert-butyl... Agent: Medtronic Vascular, Inc.IPLegal Department

20080254087 - Methods for administering hypoglycemic agents: The present invention relates to methods of administering hypoglycemic agents and/or GLP-1 agonists.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080254089 - Pharmaceutical products comprising bisphosphonates: A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a... Agent: Novartis Corporate Intellectual Property

20080254088 - Shaped bodies based on a cross-linked, gelatinous material, method for producing such bodies and use of the bodies: Shaped bodies based on gelatin which have both high mechanical strength and also sufficient flexibility are provided, the shaped body comprising a cross-linked, gelatinous material which comprises gelatin and a plasticizer, the shaped body being stretched so that the gelatin molecules are oriented at least in part in a preferred... Agent: Leydig Voit & Mayer, Ltd

20080254092 - Acellularized biomaterial from embryonic stem cells: Compositions containing acellularized biomaterial derived from differentiating pluripotent cells, for example, embryonic stem cells are provided. The acellularized biomaterial can be used to promote wound healing, promote tissue regeneration, or inhibit scarring. Methods for using the acellularized biomaterial for treating degenerative diseases are also provided.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080254093 - Compositions and minimally invasive methods for treating dysfunction of cardiac muscle: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is described.... Agent: Knobbe Martens Olson & Bear LLP

20080254091 - Multi-layered antiadhesion barrier: The present invention relates to a multi-layered anti-adhesion barrier, particularly to a multi-layered anti-adhesion barrier comprising a nanofibrous structured base layer electrospun from a hydrophobic, biodegradable, biocompatible polymer and a polymer layer formed by coating a hydrophilic, biooriginated polymer on the base layer, and a method for the preparing the... Agent: Ipla P.A.

20080254090 - Porcine islets cultured with porcine sertoli cells for xenotransplantation: Aggregates and their method of preparation suitable for implantation into a recipient in order to produce insulin in vivo. The methods involve culturing islet cells isolated from the pancreas of donor piglets with isolated Sertoli cells from the testes of donor piglets. A preferred period of culturing is 5 days... Agent: Mark D Moore Haynes And Boone

20080254094 - Biomaterials carrying cyclodextrines having improved absorption properties and used for the progressive and delayed release of therapeutic molecules: g

20080254095 - Delivery device and method for forming the same: A delivery device includes a hollow container, and a plurality of biodegradable and/or erodible polymeric layers established in the container. A layer including a predetermined substance is established between each of the plurality of polymeric layers, whereby degradation of the polymeric layer and release of the predetermined substance occur intermittently.... Agent: Julia Church Dierker Dierker & Associates, P.C.

20080254096 - Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix... Agent: Stephen Donovan

20080254097 - Method and implant material for treatment of urinary incontinence: Methods and implant materials are provided for treating urinary incontinence. The methods may include providing a composition that includes at least one pharmaceutically active formulation capable of retropubic fat dissolution; and introducing the composition into the retropubic space, preferably via a minimally invasive procedure, to contact adjacent tissue and promote... Agent: Sutherland Asbill & Brennan LLP

20080254098 - Neural tube birth defect reduction with folic acid delivery in catamenial hygiene products: A method and apparatus of fortifying a population of fertile age women with folic acid to reduce the incidence of neural tube birth defects involves placing folic acid either in powder, microcapsule, gel, cream, tablet, capsule or other form in or on a feminine hygiene product such as a tampon... Agent: Steven Horowitz, Esq.

20080254100 - Methods of using gamma cyclodextrin to control blood glucose and insulin secretion: Disclosed are methods of producing a blunted postprandial glycemic response in an individual, and/or reducing postprandial insulin secretion, said methods comprising administering to the individual a nutritional or other product comprising gamma-cyclodextrin. Also disclosed are similar other methods directed toward the use of such products to provide weight and appetite... Agent: Patent Docket Department Armstrong Teasdale LLP

20080254099 - Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and... Agent: Wells St. John P.s.

20080254101 - Pilocarpine compositions and methods of use thereof: The present invention provides novel compositions for the delivery of pilocarpine or a pharmaceutically acceptable salt thereof across the oral mucosa, preferably across the buccal mucosa. In particular, the buffer systems in the compositions of the present invention contain an amount of a strong base that is less than the... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20080254102 - Orally administered agent and an orally administered agent/supporting substrate complex: With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent 1b having one drug-containing layer 11 and two water-swellable gel-forming layers 12, the... Agent: Posz Law Group, PLC

20080254104 - Advanced functional biocompatible polymeric matrix containing nano-compartments: The present invention provides a novel biomaterial which is a hybrid, self-assembling biopolymeric networked film that is functionalized through hydrophobic interactions with vesicles loaded with bioactive agents. The biomaterial compound is a polymeric network of hydrophobically modified chitosan scaffolds that is taken from solution and formed as a solid film.... Agent: Whiteford, Taylor & Preston, LLP Attn: Gregory M Stone

20080254103 - Wound dressings comprising a protein polymer and a polyfunctional spacer: There is described a method of forming a wound dressing. The method comprises forming a protein polymer by reacting a protein with a polyfunctional spacer, or an activated derivative thereof. The polyfunctional spacer is preferably a polycarboxylic acid, especially a dicarboxylic acid, and protein polymers prepared using such spacers are... Agent: Davis Wright Tremaine LLP/los Angeles

20080254105 - Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080254106 - Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis: The present invention relates to the use of Pirlindole, if needed with suitable adjuvants and additives for the production of a medicament for the treatment of diseases characterized by hyperproliferation of keratinocytes and/or T cells, in particular psoriasis and neurodermatitis as well as compositions comprising Pirlindole and use thereof.... Agent: Hahn & Voight PLLC

20080254107 - Method and device for treating bursitis: The present invention relates to a method for treating a subject for a condition or inflammation associated with oedema, excess body fluids or oedema and excess body fluids, or for treating a subject for an abscess, boil, blister or cyst. The method comprises applying to the skin surface covering a... Agent: Knobbe Martens Olson & Bear LLP

20080254108 - Formulations and methods for modulating satiety: This disclosure relates to formulations and methods of suppressing appetite and eliciting satiety (sense of being filled) in mammals through the oral administration of an effective amount of an appetite suppressing moiety.... Agent: Mcdermott Will & Emery LLP

20080254109 - Localized myocardial injection method for treating ischemic myocardium: This invention relates to a method of treating ischemic or diseased myocardium by injecting a therapeutic agent, such as a gene, protein, cell or drug, into normal myocardium, preferably adjacent to an ischemic zone in the heart of a subject. The method is useful for inducing angiogenesis and collateral blood... Agent: Fulbright & Jaworski L.L.P.

20080254110 - Composition for enhancing immunity and reducing inflammation related to infections: A composition and method for enhancing immunity and reducing or inhibiting inflammation related innate immune system activation while affording the body of a user protection against known detrimental byproducts of immune-response is provided. The composition comprises at least a therapeutically effective amount of vitamin C and extract of Andrographis paniculata.... Agent: Iovate Health Science Research Inc.

20080254111 - Bandseal for peg-filled hard capsule: The present invention provides a band seal for hard capsules filled with PEG, particularly a low-molecular-weight PEG, PEG 200 to 600, the band seal being capable of effectively preventing content leakage through the gap between the body and cap of the capsule; and a liquid for preparing the band seal.... Agent: Fitch, Even, Tabin & Flannery

20080254114 - Controlled release compositions comprising heterocyclic amide derivative nanoparticles: The present invention is directed to compositions comprising nanoparticulate heterocyclic amide derivative and preferably zafirlukast nanoparticles, also collectively referred to as “active ingredient,” having improved solubility in water. The nanoparticles of the composition have an effective average particle size of less than about 2,000 nm, and are useful in the... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20080254116 - Delta and epsilon crystal forms of imatinib mesylate: The invention relates to the delta and epsilon crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (the compound of formula I, see below), certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals,... Agent: Novartis Corporate Intellectual Property

20080254113 - Microemulsion formulations comprising particular substance p antagonists: The present invention relates to dispersible pharmaceutical compositions in which the active agent is a substance P antagonist, in particular a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide, that is useful for the treatment and prevention of respiratory diseases including asthma and chronic obstructive pulmonary disease, bowel disorders including irritable bowel syndrome (IBS), urinary... Agent: Novartis Corporate Intellectual Property

20080254115 - Micropellet containing pellets and method of preparing such pellets: The invention provides novel pellets adapted for biologically active preparations and a novel process for preparing said pellets. The novel pellets are adapted for use in the delivery of a biologically active agent. The pellets have an inner zone comprising a plurality of micropellets which are bound together to form... Agent: Hedman & Costigan P.C.

20080254112 - Pharmaceutical active-ingredient-containing formulation with coating: The invention relates to a pharmaceutical active-ingredient-containing formulation for oral administration which is coated with a single coating of a film-forming polymer, the coating comprising a mixture of at least two separating agents and no stabilizer.... Agent: Ronald R. Santucci Frommer Lawrence & Haug

20080254119 - Imbedded liquid lubricants for tableting: The invention provides a nutritional supplement and/or pharmaceutical composition for tableting comprising an embedded lubrication matrix. The embedded lubrication matrix comprises an oily liquid finely dispersed in an oil insoluble material. A method of lubricating a nutritional supplement or pharmaceutical composition for tableting using a matrix with embedded lubrication is... Agent: Wyeth Patent Law Group

20080254117 - Process for preparing pramipexole dihydrochloride tablets: The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit enhanced storage stability properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080254118 - Process for preparing pramipexole dihydrochloride tablets: The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit enhanced storage stability properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080254120 - Orally-disintegrating tablet and manufacturing method thereof: An orally-disintegrating tablet comprises a principal agent, a sugar alcohol powder and a sugar alcohol granule, wherein the orally-disintegrating tablet has a hardness of 30 N or greater. According to the present invention, a smooth swallowing orally-disintegrating tablet, for which both the mechanical strength and the disintegration properties in the... Agent: Sughrue Mion, PLLC

20080254121 - Multi-layer melatonin composition: A multi-layered solid dosage form for oral administration for a multi-phasic controlled release of Melatonin is described. The solid dosage form is useful as a composition to promote and maintain a state of sleep in an individual.... Agent: Iovate Health Science Research Inc.

20080254124 - Controlled release composition: A composition for controlled delivery of at least one active substance into an aqueous medium by erosion at a preprogrammed rate of at least one surface of the composition, comprising a matrix comprising the active substance, the matrix being erodible in the aqueous medium in which the composition is to... Agent: Foley And Lardner LLP Suite 500

20080254123 - Morphine polymer release system: A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and,... Agent: Foley And Lardner LLP Suite 500

20080254122 - Polymer release system: A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature.... Agent: Foley And Lardner LLP Suite 500

20080254125 - Processing of chitosan and chitosan derivatives: An article containing N-acylchitosan is manufactured by a process comprising the steps of providing a mixture containing chitosan and/or N-acylchitosan, and extruding the mixture to form an N-acylchitosan hydrogel. Alternatively, the process comprising the steps of providing a chitosan and/or N-acylchitosan hydrogel, and extruding the hydrogel. An article with a... Agent: Foley & Lardner LLP

20080254126 - Composition comprising nanoparticle ginkgo biloba extract with the effect of brain function activation: To supply the ginkgo biloba extract which contains no ginkgolic acid but the active ingredient of existing ginkgo biloba extract and which achieves significant effects in activation of the brain cells. The composition comprises nanoparticle ginkgo biloba extract as the active ingredient, which has the effect of brain function activation.... Agent: Shinji Shimada

20080254127 - Inhalation particles incorporating a combination of two or more active ingredients: Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalation particles of the invention are particularly useful in the administration of a combination medicament,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080254128 - Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same: The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080254130 - Skin antiaging & brightening via multi-function treatment of enzyme dysfunction: The present invention relates to a topical method of treatment for dysfunction of certain dermal enzymes, and the treatment of skin condition or disorder caused by said dysfunction. The said method of treatment consists of (i) an extra-cellular, matrix metalloprotease regulating agent, and (ii) an intra-cellular ubiquitin—proteasome regulating agent, and... Agent: Shyam K. Gupta Bioderm Research

20080254129 - Use of avian anti-methanogen antibodies for reduction of methane production: Herein, it is shown that strong specific anti-methanogen avian antibodies can be produced when chickens are immunized with an optimal dose of methane producing bacterial antigen (methanogen) formulated with an appropriate adjuvant. The antibodies can in turn be used to reduce methane gas production from an animal by administering an... Agent: Ade & Company Inc.

20080254131 - Controlled-release galantamine formulations: Controlled-release galantamine formulations, including controlled-release particles, pellets, granules, and spheres are described. Controlled-release particles, pellets, granules, and spheres with immediate release top-coat are also described. Method of preparing such formulations and method of treating a variety of disorders are also disclosed.... Agent: Cantor Colburn, LLP

20080254132 - High pressure spray-dry of bioactive materials: This invention provides compositions and methods providing, e.g., stable powder particles containing bioactive materials. The methods include, e.g., high pressure spraying of the bioactive materials in solution or suspension, with viscosity enhancing agents and/or surfactants. Compositions of the invention provide, e.g., high initial purity, high stability in storage, and reconstitution... Agent: Quine Intellectual Property Law Group, P.C.

20080254134 - Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof: A method of inducing either a TH1 polarised immune response, a TH2 polarised immune response or a combined TH1 and TH2 response to an antigen and associated vaccine formulations are disclosed. A method is provided for inducing a polarised TH1 response by parenteral administration of microparticles sized such that at... Agent: Myers Bigel Sibley & Sajovec

20080254133 - Microgel particle: The present invention relates to compositions comprising a pH-responsive microgel particle, wherein the particle is adapted to undergo a conformational change in response to a variation in pH. The compositions may be used as medicaments for treating a disease characterised by damaged or degenerated soft tissues (e.g. intervertebral discs).... Agent: Davis Wright Tremaine LLP/los Angeles

20080254135 - Resveratrol-containing compositions for general health and vitality: The present invention is directed towards an orally administered composition comprising multiple plant extracts, which are characterized as having high ORAC values, and promote an increase in a mammal's dietary intake of antioxidant and polyphenols to a therapeutically effective amount. The ingredients of the present compositions represent a broad spectrum... Agent: Torys LLP

20080254136 - Antiprotozoal agent: e

20080254137 - Treatment of autoimmune disorders using detoxified cobratoxin: Autoimmune disorders are widespread diseases with many manifestations. Immune regulatory dysfunction is central to the progress of these diseases. The control this dysfunction can be achieved through intervention in the immune pathways. The balance of regulatory cytokines is central to a correctly functioning immune system and is a target for... Agent: Robert J. Van Der Wall Gables One Tower

20080254138 - Extracellular matrix to recruit stem cells to a site of malignancy: The invention is to a method of recruiting stem cells to a site of malignancy by contacting the site with exogenous mammalian extracellular matrix in the form of a sheet article, or a composition comprising particulate extracellular matrix, or emulsion or gel extracellular matrix.... Agent: Leigh Hunt Firestone

20080254139 - Methods and compositions to treat ovarian cancer: The invention is a method of treating ovarian cancer by contacting a post-surgical site of an ovarian cancer patient with a composition or a sheet article comprising extracellular matrix to inhibit cancer cell attachment, promote wound healing after the surgery, reduce scar formation at the surgical site, regenerate lost tissue,... Agent: Leigh Hunt Firestone

20080254140 - Combination methods and therapies for treating opthalmic conditions with 13-cis-retinyl derivatives: Described herein are combination methods, compositions and therapies for treating ophthalmic conditions or diseases arising from, associated with or leading to the overproduction of waste products in the visual cycle. Agents included within these combinations are 13-cis-retinyl derivatives; other agents included within these combinations are selected from vitamins, antioxidants, minerals,... Agent: Wilson Sonsini Goodrich & Rosati

20080254141 - Anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) ionic compound, and (C) an additive. The anti-bacterial, anti-virus, and... Agent: Occhiuti Rohlicek & Tsao, LLP

20080254142 - Compositions and methods for nutrition supplementation: The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, pregnant or lactating subjects.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080254144 - Beverage health formulations: Dietary supplement formulations are described that provide benefits of soluble fiber accompanied by excellent taste with many different health benefit combinations.... Agent: Michael A. Ervin

20080254143 - Composition for improving immune system health: A composition and method for enhancing the immune system of an individual is provided. The present invention enhances the functioning of the immune system through increasing the production of certain cytokines, inhibiting viral adhesion and interfering in the viral replication process. The severity and duration of infections resulting from the... Agent: Torys LLP

20080254145 - Anti-tumor drug, medicament, composition, and use thereof: The present invention relates to an active polypeptide comprising the amino acid sequence of SEQ ID NO:3, or having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO:3, or fragments thereof having at least 21 contiguous amino acids, or peptides having... Agent: Young & Thompson

20080254146 - Method of providing hemostasis in anti-coagulated blood: A method of clotting blood includes the step of administering a therapeutically effective amount of a composition comprising zeolite as the active ingredient to a wound from which the blood emanates. A method of arresting blood flowing from a wound includes the steps of providing a patient being inflicted with... Agent: Michaud-duffy Group LLP

20080254147 - Method of providing hemostasis in anti-coagulated blood: In a method of clotting blood in which the blood exhibits a reduced tendency to clot and may be from a person undergoing an anticoagulant therapy or having type A or B hemophilia or von Willebrand disease, a therapeutically effective amount of a composition comprising clay as the active ingredient... Agent: Michaud-duffy Group LLP

20080254151 - herbal mixture extract of rehmanniae radix preparata and acanthopanacis cortex and a composition comprising the same for prevention and treatment of osteoporosis:

20080254148 - Herbal compositions for the inhibition of human immunodeficiency virus: The invention provides a herbal composition for the inhibition of HIV, comprising an organic extract of Hedyotis diffusa (Oldenlandia diffusa), an organic solvent extract of Prunella vulgaris and an organic solvent extract of Viola philippica (Viola yedoensis).... Agent: Wpat, PC Intellectual Property Attorneys

20080254150 - Management of dermatitic symptoms of mammalian integument with emollient disinfectant formulations: Botanically-sourced and botanically-derived emollient sanitation compositions for topical use are disclosed. Representative compositions generally aid reconstitution of the lipid profile of the stratum corneum by providing botanical lipids and/or lipid-derivatives that resemble human sebum—these components being ordinarily diminished with the use of conventional hand sanitizer products. Disclosed features and specifications... Agent: International Flora Technologies, Ltd. C/o Intellevate LLC

20080254149 - Recovery of residual plant components after distillation of essential oils: Methods for recovering valuable compounds and substances from plants after distillation of oils are disclosed. The methods involve various aqueous and non-aqueous solvent extraction of plant material from which oils have been distilled previously.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080254152 - Methods for reducing the effects of stress on skin condition: A method is provided for reducing the effects of psychologically-mediated stress on the skin of a human or animal which method comprises administering to the individual a composition capable of inhibiting glucocorticoid-induced chronic stress in a dermal cell or a cell involved in skin inflammatory responses. Also provided are compositions... Agent: Unilever Patent Group

20080254153 - Water dispersible composition and method for preparing same: The invention pertains to a water dispersible, preferably a powder composition of water extractible bioactive components of exclusively fruit or vegetable or plant origin. These components are obtainable by: a) subjecting a selected fruit or vegetable or plant material to homogenisation in weak alkaline conditions and at moderate temperature; b)... Agent: Winston & Strawn LLP Patent Department

20080254154 - Follicle-stimulating hormone reduction agent: The composition of the present invention comprising Cucurbita moschata, Carthamus tinctorius, Plantago asiatica and Lonicera japonica has a follicle-stimulating hormone reduction action. Based on this action, the composition is usable as a preventive, remedy, health food or functional food for diseases, for example, climacteric disturbance, primary hypogonadism (including ovarian hypofunction... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080254155 - Use of ginkgo biloba extract in preparation of a composition for lowering cholesterol: The use of ginkgo biloba extract in preparation of a composition for lowering cholesterol is provided. Furthermore, the use of ginkgo biloba extract in preparation of a composition for modulating the gene expressions of key enzymes associated with cholesterol metabolism in vivo is provided. Also the use of a set... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080254156 - Pharmaceutical composition comprising plant material or trichilia sp. alone or in association with other plant extracts for the reversion/combat and/or prevention of ventricular fibrillation: The present invention relates to the use of a plant material of the species Trichilia sp., alone or in association with one or more of the following plants: Paullinia cupana (Sapindaceae), Croton moritibensis (Euphorbiaceae) and Zingiber officinale (Zingiberaceae) in the treatment, reversion, combat and/or prevention of ventricular fibrillation. A product... Agent: Alston & Bird LLP

20080254157 - Herbal composition for inflammatory disorders: This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (7-Hydroxy-4,11(13)-eudesmadien-12,6-olide) (compound 1), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (compound 1) as... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080247943 - Blood clot-targeted nanoparticles: Emulsions comprising nanoparticles formed from high boiling perfluorochemical substances, said particles coated with a lipid/surfactant coating are made target-specific by directly coupling said nanoparticles to a targeting ligand. The nanoparticle may further include biologically active agents, radionuclides, and/or other imaging agents, and are used to image and/or lyse blood clots... Agent: Morrison & Foerster LLP

20080247945 - Anti-il-20 antibodies and binding partners and methods of using in inflammation: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such... Agent: Zymogenetics, Inc. Intellectual Property Department

20080247944 - Irta-2 antibodies and their uses: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions... Agent: Baker Botts L.L.P.

20080247946 - Gastrin releasing peptide compounds: New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N—O—P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing... Agent: Kramer Levin Naftalis & Frankel LLP

20080247947 - High dose 111in-pentetreotide therapy of neuroendocrine tumors: A method for treating a neuroendocrine tumor is disclosed, which includes administering a first dose of 111In-pentetreotide to a subject having the neuroendocrine tumor; and administering a second dose of 111In-pentetreotide to the subject after a selected duration has elapsed after the administering of the first dose, wherein the first... Agent: Osha Liang L.L.P.

20080247948 - Stereoisomers of fatty acid analogs for diagnostic imaging: The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more... Agent: Foley And Lardner LLP Suite 500

20080247950 - Activation of peptide prodrugs by hk2: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods... Agent: Paul, Hastings, Janofsky & Walker LLP

20080247951 - Anti-robo4 antibodies and uses therefor: The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods.... Agent: Genentech, Inc.

20080247949 - Biological tissue examination agent comprising hemoglobin labeled with oxygen isotope and method for producing the same: The present invention relates to a biological tissue examination agent comprising hemoglobin labeled with 15O2 and a method for producing the same. More specifically, the present invention relates to a biological tissue examination agent for diagnosing a cause or condition of a disease by detecting oxygen metabolism in a biological... Agent: Birch Stewart Kolasch & Birch

20080247952 - Method for quantifying a cholinergic neurotoxin in a sample: The invention relates to a method for determining the kinetics of action of a cholinergic neurotoxin as well as a method for determining the quantity of neurotoxin in a sample.... Agent: Hunton & Williams LLP Intellectual Property Department

20080247956 - Identification of novel factors that block programmed cell death or apoptosis by targeting jnk: Methods and compositions for modulating apoptosis by acting on the c-Jun-N-terminal kinase (JNK) pathway and assays for the isolation of agents capable of modulating apoptosis, including modulators of the JNK pathway are disclosed. A method of modulating JNK pathway independent of Gadd46β is disclosed. Methods and compositions are presented for... Agent: Barnes & Thornburg LLP

20080247955 - Inflammation treatment, detection and monitoring via trem-1: The present invention provides methods of treating inflammatory diseases/disorders in a subject by inhibiting/antagonizing TREM-1 expression/activity/signal transduction and/or DAP12/TyroBP expression and/or activity. Methods of detecting the presence of inflammatory disease in a subject by detecting TREM-1 and/or DAP12/TyroBP expression and/or activity in the subject or a sample obtained therefrom, wherein... Agent: Wyeth Patent Law Group

20080247953 - Methods and compositions for affecting substrate docking of kinases in modulating cellular activities: The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. This includes primarily diseases or conditions associated with immune responses and can include treatment for cancers as well as various... Agent: Mckee, Voorhees & Sease, P.L.C

20080247954 - Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment: e

20080247957 - Advanced drug delivery strategy and platform for minimally-invasive treatment of liver cancer: The present invention comprises minimally invasive methods useful in the treatment of liver cancer. The method of the present invention comprises administering to an individual with liver cancer an injectable, echogenic nanocapsule and/or microcapsule wherein the nanocapsule and/or microcapsule comprises a therapeutic agent, a targeting moiety, or a combination thereof.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080247958 - Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use: A composition comprising an albumin-based colloid composition having at least one protected thiol region, method of making the same, and method for use, including treating hypovolemic conditions such as capillary leak syndrome and shock, are disclosed. The composition also is modified with an indicator reagent such as chromophores.... Agent: Emch, Schaffer, Schaub & Porcello Co

20080247959 - Form of administration secured against misuse: The invention relates to a form of administration which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The... Agent: Norris, Mclaughlin & Marcus, P.A.

20080247960 - Foaming tropical compositions: Improved aqueous foaming topical compositions for the application to the human body particularly to the skin which composition provides both a cleaning benefit, and a durable antimicrobial benefit.... Agent: Norris, Mclaughlin & Marcus

20080247961 - Nasally administrable compositions of zolpidem and methods of use: The present invention provides a method for inducing sleep, by nasally administrating to a subject in need thereof a pharmaceutical composition containing zolpidem, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080247962 - Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof: A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from (24) to (39) carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or derivatives thereof, preferably statins, optionally... Agent: Ladas & Parry LLP

20080247965 - Pressurised metered dose inhalers (mdi): The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is lined with an inert organic coating and which contain a formulation which comprises TA 2005.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080247963 - Quinuclidine compounds having quaternary ammonium group, its preparation method and use as blocking agents of acetylcholine: e

20080247964 - Substituted azaspiro derivatives: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals... Agent: Cantor Colburn, LLP

20080247966 - Compositions and methods to counteract oral malodour: The invention relates to hedonistically pleasing oral malodour counteracting compositions including flavour compositions and oral care products, methods to form such compositions and methods to counteract oral malodour. The compositions comprises 4 or more of oral malodour counteracting actives in a total concentration of at least 20% (w/w) based on... Agent: Norris, Mclaughlin & Marcus

20080247967 - Dentifrice with packaging layers: A dentifrice composition comprising at least one phase, wherein said dentifrice is packaged in a generally transparent container, and wherein the combination of the dentifrice and the container and/or at least one packaging layer forms a pattern.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080247968 - Multi-phase dentifrice with characters: A multi-phase dentifrice composition comprising at least two visually distinct phases, wherein said visually distinct phases are packaged in a generally transparent container, wherein at least one phase is in physical contact with another phase, and wherein the visually distinct phases form the appearance of at least one character.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080247970 - Opaque multi-phase dentifrice with alternating bands: A multi-phase dentifrice composition comprising at least two visually distinct phases wherein said visually distinct phases are packaged in a generally transparent container, at least one phase is in physical contact with another phase, all visually distinct phases are opaque, and the visually distinct phases form alternating bands wherein at... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080247969 - Opaque multi-phase dentifrice with patterns: A multi-phase dentifrice composition comprising at least two visually distinct phases wherein said visually distinct phases are packaged in a generally transparent container, wherein at least one phase is in physical contact with another phase, wherein all visually distinct phases are opaque, and wherein the visually distinct phases form any... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080247971 - Transparent multi-phase dentifrice with coils: A multi-phase dentifrice composition comprising at least two visually distinct phases wherein said visually distinct phases are packaged in a generally transparent container, at least one phase is in physical contact with another phase, at least one visually distinct phase is generally transparent, and at least one visually distinct phase... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080247972 - Mouthwash for the prevention and treatment of halitosis: The present aspects relate to a mouthwash developed to reduce and/or avoid the formation of tonsilloliths, heretofore unknown to the art, to facilitate the removal and to diminish the new formation of tongue coating and to reduce the concentration and formation of volatile sulfur compounds. In a preferred aspect, the... Agent: Amin, Turocy & Calvin, LLP

20080247973 - Compositions and methods for improving overall tooth health and appearance: Disclosed are oral care compositions comprising selected surface-active organophosphate compounds and methods of use to provide protection of teeth from erosion caused by the action of chemicals, such as harsh abrasives and acids. The surface-active organophosphate compounds are substantive to teeth, the phosphate groups binding the calcium in teeth and... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080247974 - Rooibos extract with increased aspalathin content, process for the preparation of such a rooibos extract , and cosmetic agent containing such a rooibos extract: The invention relates to a rooibos extract prepared from unfermented rooibos raw material by means of a solvent extraction, with an increased aspalathin content that is at least 5 wt %, cosmetic agents prepared from such a rooibos extract, and a process for the preparation of such a rooibos extract... Agent: The Webb Law Firm, P.C.

20080247976 - Sunscreen and personal care compositions comprising a random terpolymer: e

20080247975 - Sunscreen and personal care compositions comprising a select copolymer:

20080247977 - Anhydrous film for lip make-up or care: The invention concerns a cosmetic product for lip make-up or care in the form of an anhydrous film comprising: a) at least one water-soluble polymer, and b) at least one dye. Said anhydrous film dissolves in contact with saliva to provide lip make-up or treatment.... Agent: Oliff & Berridge, PLC

20080247978 - Underarm products with superabsorbent component: A stick or soft solid suspension product comprising: (a) 0.01-20 weight % of a polyacrylate superabsorbent polymer (sodium salt), with a salt or ionic strength tolerance under a Baseline Absorption Test sufficient to give at least 25 weight % water absorption; (b) 10-88 weight % of a volatile silicone having... Agent: Colgate-palmolive Company

20080247979 - Use of a hydrophobic zeolite, that contains and gives a slow release of an active element, for treatment of skin: The invention describes the use of a hydrophobic zeolite, that contains an active component, especially a disinfection element, as ethanol, iodine, phenol, cresol or hydrogen peroxide, in a composition for non-medical treatment of the skin, for example as a deodorant. The invention also describes the use of a hydrophobic zeolite,... Agent: Connolly Bove Lodge & Hutz LLP

20080247980 - Hair care compositions comprising a dendritic polymer: A cosmetic and personal care composition comprising a hydrophobically functionalised polyhydric dendritic macro-molecule built up from polyester or polyether units or mixtures thereof.... Agent: Unilever Patent Group

20080247981 - Vinylpyrrolidone/vinyl acetate copolymer, process for producing the same, and use of the same: To provide a vinylpyrrolidone/vinyl acetate copolymer which is extremely reduced in thermal yellowing and is usable even at high temperatures and which can dissolve in water to give a transparent solution. The vinylpyrrolidone/vinyl acetate copolymer of the present invention has a residual vinylpyrrolidone content of 100 ppm or less relative... Agent: Connolly Bove Lodge & Hutz LLP

20080247982 - Hair treatment product containing anionic and cationic surfactants: The invention relates to a hair treatment product containing a1) alkyl ether sulfate or a2) alkyl sulfate or the mixture thereof, b) secondary alkane sulfonate, c1) betaine or c2) ether carboxylate or the mixture thereof, d) at least one non-ionic surfactant, and e) a cationic surfactant.... Agent: Clariant Corporation Intellectual Property Department

20080247983 - Hair pomade composition and method of making the same: The method for making a hair pomade composition includes the steps of melting petroleum jelly over a heated surface and then mixing sesame seed oil, meadowfoam seed oil, pumpkin seed oil, Cyprus oil, basil sweet oil, Rosemary oil, black pepper oil, lemon oil, and Anise oil with the melted petroleum... Agent: Kelly Lowry & Kelley, LLP

20080247984 - Dopa-functionalized, branched, poly(aklylene oxide) adhesives: The invention describes DOPA functionalized, branched, polyalkylene oxide materials that are useful as adhesives.... Agent: Northwestern University C/o Quarles & Brady LLP

20080247985 - Composition base containing solubilized allantoin and urea for topical preparations: Substantially homogeneous topical preparations for cosmetic, veterinary, and pharmaceutical use comprise at least one active ingredient solubilized in a novel composition base. The composition base comprises solubilized allantoin at a level of at least 0.5% and urea at a level of at least 10% in an aqueous vehicle.... Agent: Jerry Zhang

20080247986 - Hyaluronidase inhibitor containing poly-gamma-glutamic acid as an effective component: The present invention relates to a hyaluronidase inhibitor containing poly-gamma-glutamic acid (PGA) as an active ingredient, a composition for maintaining skin elasticity and a composition for improving allergy, wherein each of the compositions contains PGA as an active ingredient. The inventive compositions containing PGA are effective in maintaining skin moisturization... Agent: Moore & Van Allen PLLC

20080247987 - Block copolymer compositions and uses thereof: The present invention describes compositions, devices, and methods for the production, use and administration of the composition having a non-thermoreversible block copolymer composition.... Agent: Seed Intellectual Property Law Group PLLC

20080247988 - Methods of making and using surfactant polymers: Comblike, surfactant polymers for changing the surface properties of biomaterials are provided. Such surfactant polymers comprise a polymeric backbone of repeating monomeric units having functional groups for coupling with side chains, a plurality of hydrophobic side chains linked to said backbone via the functional groups, and a plurality of hydrophilic... Agent: Pearne & Gordon LLP

20080247990 - Genetically modified human natural killer cell lines: The invention provides a natural killer cell, NK-92, modified to express a CD16 receptor or an inhibitory killer cell immunoglobulin-like receptor (KIR) on a surface of the cell. In examples, the NK-92 cell is further modified to co-express an associated accessory signaling protein such as FcεRI-γ or TCR-ζ, chemokines, or... Agent: Cohen & Grigsby, P.C.

20080247989 - Reishi - mediated enhancement of human tissue progenitor cell adhesion and differentiation: The present disclosure provides medicinally active extracts and fractions, and methods for using the same to increase eukaryotic cell adhesion, to increase differentiation of eukaryotic cells to produce increased numbers of B cells dendritic cells and chodrocytes, and to maintain undifferentiated hematopoietic cells. These methods and useful for modulating immune... Agent: Greenberg Traurig LLP (la)

20080247991 - Solution additives for the attenuation of protein aggregation: In part, the present invention relates to a compound or polymer comprising a non-protein-binding moiety and at least one protein-binding group. The present invention relates to a method of screening compounds or polymers for the property of inhibiting protein aggregation in solution, a method of preparing a compound or polymer... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080247992 - Nitrogen-containing heteroaryl derivatives: Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.... Agent: Genelabs Technologies, Inc. C/o Foley & Lardner LLP

20080247993 - Microorganisms inhibiting the formation of axillary malodor: Described are microorganisms which are able to suppress the production of malodorous compounds by axillary bacteria. Also described are compositions comprising such microorganisms as well as the use of such micoorganisms in cosmetic, prophylactic or therapeutic applications.... Agent: Connolly Bove Lodge & Hutz, LLP

20080247994 - Dna vaccine: The present invention relates to a DNA vaccine consisting of a vector expressing a part or the whole of a polypeptide regulating production of an inflammatory cytokine, a pharmaceutical composition comprising the DNA vaccine, and a method of preventing or treating an inflammatory disease by using the pharmaceutical composition.... Agent: Foley And Lardner LLP Suite 500

20080247996 - Methods of treating neoplasia with combination target cell-specific adenovirus, chemotherapy and radiation: The invention provides methods of treating neoplasia using combinations of target cell-specific replication competent adenoviral vectors and chemotherapy, radiation therapy or combinations thereof. The adenoviral vectors are target cell-specific for the particular type of neoplasia for which treatment is necessary and the combination with the chemotherapy and/or radiation leads to... Agent: Ropes & Gray LLP

20080247995 - Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide: The present disclosure provides nucleic acid constructs encoding one or more polypeptides containing at least one glycosaminoglycan chain, such as, but not limited to, a proteoglycan polypeptide, and methods for delivering to the site of a wound or cutaneous injury at least one nucleic acid construct encoding one or more... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20080248007 - B7-h5, a costimulatory polypeptide: B7-HS costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.... Agent: Fish & Richardson P.C.

20080248010 - Compositions and methods of using apoptosis signaling kinase related kinase (askrk): The invention provides apoptosis signaling kinase related kinase (ASKRK) nucleic acid and polypeptide sequences and methods of using such sequences to identify modulators of ASKRK. Such modulators can be used for the treatment of diabetes or for delaying the onset of diabetes. The invention also provides methods of diagnosing diabetes... Agent: Townsend And Townsend And Crew, LLP

20080248008 - Inhibitors of protein kinase a anchoring: A PKA I anchoring disrupting molecule or AKAP mimic, wherein said molecule or mimic is a polypeptide which comprises the following amino acid sequence: X1 X2 X3 Y A X4 X5 L A X6 X7 X8 I X9 X10 X11 X12 X13 (sequence (1)) or a peptidomimetic or analogue thereof... Agent: Knobbe Martens Olson & Bear LLP

20080248009 - Regulation of acheron expression: The invention relates to novel apoptosis-associated nucleic acids and polypeptides and methods for use thereof, including methods of treatment of disorders associated with aberrant cellular proliferation, differentiation, or degeneration. Included are methods of enhancing the success of cell transplantation and cell-based genetic therapy procedures.... Agent: Fish & Richardson PC

20080247997 - External animal layer sanitation using bacteriophage: Methods for disinfecting external layers from animals include applying phage to the external layers. Phage may be applied before an external layer is removed from a remainder of an animal's body, during the removal process, or following removal of the external layer from the remainder of the animal's body.... Agent: Trask Britt

20080248002 - Anti-angiogenic cellular agent for cancer therapy: The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When... Agent: Beyer Weaver LLP

20080248004 - Cell fractions containing cells capable of differentiating into neural cells: Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.... Agent: Foley And Lardner LLP Suite 500

20080247998 - Creation of a biological atrioventricular bypass to compensate for atrioventricular block: A method of creating an atrioventricular bypass tract for a heart comprises growing mesenchymal stem cells into a strip with two ends, attaching one end of the strip onto the atrium of the heart, and attaching the other end of the strip to the ventricle of the heart, to create... Agent: Kenyon & Kenyon LLP

20080248005 - Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom: The present invention relates to a skin equivalent and a method for producing the same, wherein the skin equivalent comprises a scaffold and stem/progenitor cells isolated from the amniotic membrane of umbilical cord. These stem/progenitor cells may be mesenchymal (UCMC) and/or epithelial (UCEC) stem cells, which may then be further... Agent: Biotechnology Law Group C/o Portfolioip

20080248003 - Methods and compositions for growing adipose stem cells: The present invention relates to adipose tissue-derived stem cells and to methods and compositions for enhancing growth and differentiation of such cells. The invention further relates to growing such cells in serum-free or low serum growth medium, and formulations thereof.... Agent: University Of Virginia Patent Foundation

20080248001 - Methods and systems for treating cell proliferation disorders: e

20080248006 - Process for ex vivo formation of mammalian bone and uses thereof: The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of... Agent: Fulbright & Jaworski L.L.P.

20080248000 - Stem cells, method for their purification, identification, and use: Herein is described a new population of circulating CD14+cells, with a low density surface expression of CD34 and endowed with stem capacity, a method for their purification and identification, and their therapeutic use.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080247999 - Treating cancer: The present invention provides a peptide comprising an amino acid sequence that is part of the amino acid sequence of CDK4 protein, or homologous to part of the amino acid sequence of CDK4 protein, which peptide is cytotoxic to, and/or inhibiting to the growth of, a cancer cell and/or stimulating... Agent: Dechert LLP

20080248011 - Methods for isolating monocytes: The present invention provides HIDE1 as novel monocyte markers. Since HIDE1 are membrane proteins, monocytes can be specifically detected by using antibodies that bind to HIDE1. Further, HIDE1-positive monocytes can also be collected from peripheral blood or the like using a cell sorter, magnet, or such. Monocytes that can be... Agent: Townsend And Townsend And Crew, LLP

20080248012 - Erythrocyte function modifying substance: A promoter of ATP release from red blood cells, comprising a substance capable of stabilizing the structure of hemoglobin in red blood cells in its T-state; and a method of releasing ATP from red blood cells with the use of the promoter. There are further provided an inhibitor of ATP... Agent: Dickstein Shapiro LLP

20080248014 - Animal medicament and method of manufacture: A medicament for administration to a non-human animal, wherein the medicament includes at Least partially hydrolysed protein and one or more pharmacologically active substances. In a preferred embodiment, the protein is derived from meat which is hydrolysed using a fruit-derived proteolytic enzyme such as actinidin from kiwifruit which enhances the... Agent: Young & Thompson

20080248013 - Coenzyme q10- containing composition: m

20080248015 - Methods and kits for co-administration of nutritional supplements: The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, comprise co-administering one composition comprising vitamin B6, vitamin B12, folic acid, and CoQ10 and a second composition comprising omega-3 fatty acids for nutritional supplementation in order to prevent, treat and/or alleviate... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080248017 - Methods and devices for the sustained release of multiple drugs: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The... Agent: Nutter Mcclennen & Fish LLP

20080248016 - Novel iaccase enzymes and their uses: The present invention relates to novel laccase enzymes obtainable from the strains of the genus Thielavia or from the strains of the genus Chaetomium. The invention relates also to nucleic acid sequences encoding the enzymes, recombinant hosts into which the nucleic acid sequences have been introduced and to methods for... Agent: Dodds & Associates

20080248018 - Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation: The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.... Agent: EagleIPLimited

20080248020 - Heparanases and splice variants thereof, ponucleotides encoding them and uses thereof: The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to Spalax heparanases, and to Spalax and human heparanase splice variants. Heparanase splice variants can be used, for example, to modulate the activity of heparanase in diseases disorders or conditions caused by... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080248019 - Recombinant beta-galactosidase derived from streptococcus pneumaniae: The present invention relates to a novel beta-galactosidase derived from Streptococcus pneumoniae, a BgaC protein exhibiting the enzyme activity, and a method for using the same. The protein can be used in the modification and analysis of sugar chain and used as an anti-cancer agent.... Agent: Casimir Jones, S.c.

20080248021 - Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment: The present invention is directed to compositions and processes related to use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment.... Agent: Knobbe Martens Olson & Bear LLP

20080248025 - Gamma delta t cells and methods of treatment of interleukin-17 related conditions: This invention generally relates to methods to treat conditions and diseases associated with interleukin-17 (IL-17) production. The invention also relates to methods of inhibiting γδ T cells, and particularly, a subset of γδ T cells that produce IL-17.... Agent: Sheridan Ross PC

20080248027 - Method of enhancing intestinal pinocytosis of immunoglobulins in postnatal domestic mammals: Disclosed is a method of enhancing absorption (pinocytosis efficiecy) of immunoglobulins administered to postnatal domestic mammals (e.g., bovine) by using selenium. As an example of a selenium compound added, sodium selenite is particularly effective.... Agent: Day Pitney LLP

20080248023 - Prevention and treatment of amyloidogenic diseases: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20080248026 - Pten/akt methods and compositions relating to bmp: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine β-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are... Agent: Kevin C. Hooper, Esq. Bryan Cave LLP

20080248024 - Therapeutic agent for cancer, inflammation, and auto-immune disease containing inhibitor of zinc finger protein 91: The present invention relates to a use of ZFP91 based on the functions of ZFP91 (Zinc Finger Protein 91) and the interaction of ZFP91 with NF-κB (Nuclear factor kappa B) signal transduction pathway proteins, more precisely a method to inhibit the activation of NF-κB alternative pathway by regulating ZFP91 activation,... Agent: Klarquist Sparkman, LLP

20080248022 - Therapeutic strategy for treating autoimmune and degenerative diseases: Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases. In addition, the present invention relates to the determination that regulator cells are cycling in degenerative diseases. Based on these realizations, the present invention... Agent: Faegre & Benson LLP Patent Docketing

20080248031 - Cell surface molecule mediating cell adhesion and signal transmission: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and... Agent: Fish & Richardson PC

20080248032 - Compositions and methods for protection against cardiac and/or central nervous system tissue injury by inhibiting sphingosine-1-phosphate lyase: The present invention relates generally to the prevention and/or treatment of cardiac and stroke injury. In particular, the present invention provides compositions and methods for preventing and treating tissue injury in cardiac and stroke settings and injury due to ischemia/reperfusion, hypoxia, cardiotoxicity of certain therapeutic regimens, and other causes, by... Agent: Seed Intellectual Property Law Group PLLC

20080248028 - Immunoglobulin variants outside the fc region: The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application.... Agent: Morgan, Lewis & Bockius, LLP

20080248030 - Method of treating angiogenic diseases: The present invention relates to methods for treating cancer comprising administering an anti-VEGF (vascular endothelial growth factor) monoclonal antibody (e.g. Avastin) and a N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-TNP-470 conjugate (e.g. Caplostatin) to a patient in need thereof.... Agent: David S. Resnick

20080248034 - Methods for inhibiting the binding of endosialin to ligands: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods... Agent: Woodcock Washburn LLP

20080248035 - Pharmaceutical combination: This invention relates to a combination product or medicament comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof. Also provided herein are the pharmaceutical compositions comprising at least one novel substituted pyrrole derivative and one or... Agent: Sheridan Ross PC

20080248029 - Prevention and treatment of amyloidogenic diseases: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20080248033 - Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an... Agent: Clark & Elbing LLP

20080248039 - Antibodies against histone modifications for clinical diagnosis and pr